Noradrenergic mechanisms in neurodegenerative diseases: A theory

Brain Research Reviews

Volumn 45, Issue 1, 2004, Pages 38-78

  Marien, Marc R ^a   Colpaert, Francis C ^a   Rosenquist, Alan C ^a,b  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alpha2 adrenoceptors; Alzheimer's disease; Degenerative disease; Disorders of the nervous system; Noradrenaline; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 BROMO N (2 CHLOROETHYL) N ETHYLBENZYLAMINE; ADRENERGIC RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ATIPAMEZOLE; BRAIN DERIVED NEUROTROPHIC FACTOR; BRIMONIDINE; CLONIDINE; DEXEFAROXAN; GUANABENZ; IDAZOXAN; IMIDAZOLE; NERVE GROWTH FACTOR; NEUROTRANSMITTER; NORADRENALIN; PHENTOLAMINE; RESERPINE; UNCLASSIFIED DRUG; YOHIMBINE;

ALZHEIMER DISEASE; ATTENTION; BASEMENT MEMBRANE; BEHAVIOR; BODY TEMPERATURE; BRAIN CORTEX; BRAIN INJURY; BRAIN NERVE CELL; CELL ACTIVITY; CELL LOSS; CELL METABOLISM; CHOLINERGIC SYSTEM; CLINICAL FEATURE; COGNITION; CYTOTOXICITY; DEGENERATIVE DISEASE; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SELECTIVITY; ELECTROPHYSIOLOGY; ENCEPHALITIS; ENERGY METABOLISM; HIPPOCAMPUS; HUMAN; LOCUS CERULEUS; LOW DRUG DOSE; MEMORY; MOTOR PERFORMANCE; NERVE CELL LESION; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROCHEMISTRY; NEUROPROTECTION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NORADRENERGIC SYSTEM; OLFACTORY SYSTEM; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; THEORY;

EID: 1942516961     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2004.02.002     Document Type: Review

References (574)

1. Abercrombie E.D., Zigmond M.J. Partial injury to central noradrenergic neurons: reduction of tissue norepinephrine content is greater than reduction of extracellular norepinephrine measured by microdialysis. J. Neurosci. 9:1989;4062-4067.
2. Ader J.P., Room P., Postema F., Korf J. Bilaterally diverging axon collaterals and contralateral projections from rat locus coeruleus neurons, demonstrated by fluorescent retrograde double labeling and norepinephrine metabolism. J. Neural Transm. 49:1980;207-208.
3. Adolfsson R., Gottfries C.G., Roos B.E., Winblad B. Changes in the brain catecholamines in patients with dementia of Alzheimer type. Br. J. Psychiatry. 135:1979;216-223.
4. Agid Y. Parkinson's disease: pathophysiology. Lancet. 337:1991;1321-1324.
5. Agnati L.F., Zoli M., Biagini G., Fuxe K. Neuronal plasticity and ageing processes in the frame of the 'Red Queen Theory'. Acta Physiol. Scand. 145:1992;301-309.
6. Akaneya Y., Tsumoto T., Kinoshita S., Hatanaka H. Brain-derived neurotrophic factor enhances long-term potentiation in rat visual cortex. J. Neurosci. 17:1997;6707-6716.
7. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging. 21:2000;383-421.
8. Alaniz R.C., Thomas S.A., Perez-Melgosa M., Mueller K., Farr A.G., Palmiter R.D., Wilson C.B. Dopamine beta-hydroxylase deficiency impairs cellular immunity. Proc. Natl. Acad. Sci. U. S. A. 96:1999;2274-2278.
9. Albers D.S., Sonsalla P.K. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: pharmacological profile of protective and nonprotective agents. J. Pharmacol. Exp. Ther. 275:1995;1104-1114.
10. Albin R.L., Greenamyre J.T. Alternative excitotoxic hypotheses. Neurology. 42:1992;733-738.
11. Alderson R.F., Alterman A.L., Barde Y.A., Lindsay R.M. Brain-derived neurotrophic factor increases survival and differentiated functions of rat septal cholinergic neurons in culture. Neuron. 5:1990;297-306.
12. Ali S.F., Newport G.D., Slikker W. Jr. Methamphetamine-induced dopaminergic toxicity in mice. Role of environmental temperature and pharmacological agents. Ann. N.Y. Acad. Sci. 801:1996;187-198.
13. Alonso-Vanegas M.A., Fawcett J.P., Causing C.G., Miller F.D., Sadikot A.F. Characterization of dopaminergic midbrain neurons in a DBH:BDNF transgenic mouse. J. Comp. Neurol. 413:1999;449-462.
14. Aloyz R., Fawcett J.P., Kaplan D.R., Murphy R.A., Miller F.D. Activity-dependent activation of TrkB neurotrophin receptors in the adult CNS. Learn. Mem. 6:1999;216-231.
15. Altar C.A., Marien M.R. Preservation of dopamine release in the denervated striatum. Neurosci. Lett. 96:1989;329-334.
16. Altar C.A., Marien M.R., Marshall J.F. Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J. Neurochem. 48:1987;390-399.
17. Altman J. Programmed cell death: the paths to suicide. Trends Neurosci. 15:1992;278-280.
18. Andrade R., Aghajanian G.K. Opiate- and alpha 2-adrenoceptor-induced hyperpolarizations of locus ceruleus neurons in brain slices: reversal by cyclic adenosine 3′:5′-monophosphate analogues. J. Neurosci. 5:1985;2359-2364.
19. Antelman S.M., Caggiula A.R. Norepinephrine-dopamine interactions and behavior. Science. 195:1977;646-653.
20. Antelman S.M., Caggiula A.R. Norepinephrine-dopamine interactions: one step beyond. Briley M., Marien M. Noradrenergic Mechanisms in Parkinson's Disease. 1994;127-138 CRC Press, Boca Raton.
21. Aoki C. Beta-adrenergic receptors: astrocytic localization in the adult visual cortex and their relation to catecholamine axon terminals as revealed by electron microscopic immunocytochemistry. J. Neurosci. 12:1992;781-792.
22. Aoki C., Joh T.H., Pickel V.M. Ultrastructural localization of beta-adrenergic receptor-like immunoreactivity in the cortex and neostriatum of rat brain. Brain Res. 437:1987;264-282.
23. Aoki C., Go C.G., Venkatesan C., Kurose H. Perikaryal and synaptic localization of alpha 2A-adrenergic receptor-like immunoreactivity. Brain Res. 650:1994;181-204.
24. Appel S.H. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer's disease. Ann. Neurol. 10:1981;499-505.
25. Araujo D.M., Chabot J.G., Quirion R. Potential neurotrophic factors in the mammalian central nervous system: functional significance in the developing and aging brain. Int. Rev. Neurobiol. 32:1990;141-174.
26. Arima K., Akashi T. Involvement of the locus coeruleus in Pick's disease with or without Pick body formation. Acta Neuropathol. (Berl.). 79:1990;629-633.
27. Armah B.I. Unique presynaptic alpha 2-receptor selectivity and specificity of the antihypertensive agent moxonidine. Arzneimittelforschung. 38:1988;1435-1442.
28. Arnsten A.F. Catecholamine modulation of prefrontal cortical cognitive function. Trends Cogn. Sci. 2:1998;436-447.
29. Arnsten A.F., Goldman-Rakic P.S. Catecholamines and cognitive decline in aged nonhuman primates. Ann. N.Y. Acad. Sci. 444:1985;218-234.
30. Ashby C.R. Jr., Tassin J.P. The modulation of dopaminergic transmission by norepinephrine. Ashby C.R. Modulation of Dopaminergic Neurotransmission by Other Neurotransmitters. 1996;1-54 CRC Press, Boca Raton, FL.
31. Aston-Jones G., Shipley M.T., Chouvet G., Ennis M., van Bockstaele E., Pieribone V., Shiekhattar R., Akaoka H., Drolet G., Astier B., Charléty P., Val11entino R.J., Williams J.T. Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog. Brain Res. 88:1991;47-75.
32. Aston-Jones G., Rajkowski J., Kubiak P., Alexinsky T. Locus coeruleus neurons in monkey are selectively activated by attended cues in a vigilance task. J. Neurosci. 14:1994;4467-4480.
33. Aston-Jones G., Shipley M., Grzanna R. The locus coeruleus, A5 and A7 noradrenergic cell groups. Paxinos G. The Rat Nervous System. 1995;183-213 Academic Press, Boca Raton.
34. Aston-Jones G., Rajkowski J., Kubiak P. Conditioned responses of monkey locus coeruleus neurons anticipate acquisition of discriminative behavior in a vigilance task. Neuroscience. 80:1997;697-715.
35. Aston-Jones G., Rajkowski J., Cohen J. Locus coeruleus and regulation of behavioral flexibility and attention. Prog. Brain Res. 126:2000;165-182.
36. Auld D.S., Kornecook T.J., Bastianetto S., Quirion R. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog. Neurobiol. 68:2002;209-245.
37. Baker K.G., Tork I., Hornung J.P., Halasz P. The human locus coeruleus complex: an immunohistochemical and three dimensional reconstruction study. Exp. Brain Res. 77:1989;257-270.
38. Barnes C.C., Pompeiano O. Neurobiology of the Locus Coeruleus. Prog. Brain. Res. vol. 88:1991;1-642.
39. Bartus R. The cholinergic hypothesis a generation later. Emerich D., Dean R., Sanberg P. Central Nervous System Diseases. 2000;3-45 Humana Press, Totowa, NJ.
40. Bartus R.T. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 163:2000;495-529.
41. Bartus R.T., Dean R.L. III, Beer B., Lippa A.S. The cholinergic hypothesis of geriatric memory dysfunction. Science. 217:1982;408-414.
42. Baskerville K.A., Schweitzer J.B., Herron P. Effects of cholinergic depletion on experience-dependent plasticity in the cortex of the rat. Neuroscience. 80:1997;1159-1169.
43. Bauer S., Moyse E., Jourdan F., Colpaert F., Martel J.C., Marien M. Effects of the alpha(2)-adrenoreceptor antagonist dexefaroxan on neurogenesis in the olfactory bulb of the adult rat in vivo: selective protection against neuronal death. Neuroscience. 117:2003;281-291.
44. Beal M.F., Hyman B.T., Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci. 16:1993;125-131.
45. Bear M.F., Singer W. Modulation of visual cortical plasticity by acetylcholine and noradrenaline. Nature. 320:1986;172-176.
46. Beatty W.W., Rush J.R. Spatial working memory in rats: effects of monoaminergic antagonists. Pharmacol. Biochem. Behav. 18:1983;7-12.
47. Beaudet A., Descarries L. The monoamine innervation of rat cerebral cortex: synaptic and nonsynaptic axon terminals. Neuroscience. 3:1978;851-860.
48. Bedard M.A., el Massioui F., Malapani C., Dubois B., Pillon B., Renault B., Agid Y. Attentional deficits in Parkinson's disease: partial reversibility with naphtoxazine (SDZ NVI-085), a selective noradrenergic alpha 1 agonist. Clin. Neuropharmacol. 21:1998;108-117.
49. Berger-Sweeney J., Heckers S., Mesulam M.M., Wiley R.G., Lappi D.A., Sharma M. Differential effects on spatial navigation of immunotoxin-induced cholinergic lesions of the medial septal area and nucleus basalis magnocellularis. J. Neurosci. 14:1994;4507-4519.
50. Berridge C.W., Dunn A.J. DSP-4-induced depletion of brain norepinephrine produces opposite effects on exploratory behavior 3 and 14 days after treatment. Psychopharmacology (Berl.). 100:1990;504-508.
51. Berridge C.W., Waterhouse B.D. The locus coeruleus-noradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res. Brain Res. Rev. 42:2003;33-84.
52. Berridge T.W., Dettmar P.W., Doxey J.C., Gadie B., Lord J.A.H. Agonist and antagonist properties of RX 801074 at peripheral and central alpha-2 adrenoceptors in the rat. Br. J. Pharmacol. 81:1984;. (179 pp.).
53. Bezard E., Brefel C., Tison F., Peyro-Saint-Paul H., Ladure P., Rascol O., Gross C.E. Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey. Prog. Neuropsychopharmacol. Biol. Psychiatry. 23:1999;1237-1246.
54. Biggan S.L., Beninger R.J., Cockhill J., Jhamandas K., Boegman R.J. Quisqualate lesions of rat NBM: selective effects on working memory in a double Y-maze. Brain Res. Bull. 26:1991;613-616.
55. Bigl V., Schliebs R. Simulation of cortical cholinergic deficits - a novel experimental approach to study pathogenetic aspects of Alzheimer's disease. J. Neural Transm., Suppl. 54:1998;237-247.
56. Bing G., Chen S., Zhang Y., Hillman D., Stone E.A. Noradrenergic-induced expression of c-fos in rat cortex: neuronal localization. Neurosci. Lett. 140:1992;260-264.
57. Bing G., Zhang Y., Watanabe Y., McEwen B.S., Stone E.A. Locus coeruleus lesions potentiate neurotoxic effects of MPTP in dopaminergic neurons of the substantia nigra. Brain Res. 668:1994;261-265.
58. Blesch A., Grill R.J., Tuszynski M.H. Neurotrophin gene therapy in CNS models of trauma and degeneration. Prog. Brain Res. 117:1998;473-484.
59. Blokland A. Acetylcholine: a neurotransmitter for learning and memory? Brain Res. Brain Res. Rev. 21:1995;285-300.
60. Bockaert J., Homburger V., Sladeczec F. Molecular pharmacology of adrenergic receptors and their cellular localization in brain cells in culture. Heal D.J., Marsden C.A. The Pharmacology of Noradrenaline in the Central Nervous System. 1990;76-118 Oxford Univ. Press, New York.
61. Boehm S. Presynaptic alpha2-adrenoceptors control excitatory, but not inhibitory, transmission at rat hippocampal synapses. J. Physiol. 519(Pt. 2):1999;439-449.
62. Boller F., Mizutani T., Roessmann U., Gambetti P. Parkinson disease, dementia, and Alzheimer's disease: clinicopatholgical correlations. Ann. Neurol. 7:1980;329-335.
63. Bondareff W., Mountjoy C.Q., Roth M., Rossor M.N., Iversen L.L., Reynolds G.P., Hauser D.L. Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease. Alzheimer Dis. Assoc. Disord. 1:1987;256-262.
64. Bowen D.M., Smith C.B., White P., Davison A.N. Neurotransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain. 99:1976;459-496.
65. Boyd J.G., Gordon T. A dose-dependent facilitation and inhibition of peripheral nerve regeneration by brain-derived neurotrophic factor. Eur. J. Neurosci. 15:2002;613-626.
66. Boyeson M.G., Feeney D.M. Intraventricular norepinephrine facilitates motor recovery following sensorimotor cortex injury. Pharmacol. Biochem. Behav. 35:1990;497-501.
67. Boyeson M.G., Harmon R.L. Effects of trazodone and desipramine on motor recovery in brain-injured rats. Am. J. Phys. Med. Rehabil. 72:1993;286-293.
68. Boyeson M.G., Callister T.R., Cavazos J.E. Biochemical and behavioral effects of a sensorimotor cortex injury in rats pretreated with the noradrenergic neurotoxin DSP-4. Behav. Neurosci. 106:1992;964-973.
69. Boyeson M.G., Krobert K.A., Grade C.M., Scherer P.J. Unilateral, but not bilateral, locus coeruleus lesions facilitate recovery from sensorimotor cortex injury. Pharmacol. Biochem. Behav. 43:1992;771-777.
70. Bradford H.F., Zhou J., Pliego-Rivero B., Stern G.M., Jauniaux E. Neurotrophins in the pathogenesis and potential treatment of Parkinson's disease. Adv. Neurol. 80:1999;19-25.
71. Brefel-Courbon C., Thalamas C., Peyro-Saint-Paul H., Senard J.M., Montastruc J.L., Rascol O. Alpha-2 adrenoceptor antagonists - a new approch to Parkinson's disease? CNS Drugs. 10:1998;189-207.
72. Brocher S., Artola A., Singer W. Agonists of cholinergic and noradrenergic receptors facilitate synergistically the induction of long-term potentiation in slices of rat visual cortex. Brain Res. 573:1992;27-36.
73. Brown W. Alzheimer's disease, current treatments and future prospects. Financial Times Business, London, UK. 1999;1-155.
74. Bunsey M.D., Strupp B.J. Specific effects of idazoxan in a distraction task: evidence that endogenous norepinephrine plays a role in selective attention in rats. Behav. Neurosci. 109:1995;903-911.
75. Burke M.A., Mobley W.C., Cho J., Wiegand S.J., Lindsay R.M., Mufson E.J., Kordower J.H. Loss of developing cholinergic basal forebrain neurons following excitotoxic lesions of the hippocampus: rescue by neurotrophins. Exp. Neurol. 130:1994;178-195.
76. Bylund D.B., Snyder S.H. Beta adrenergic receptor binding in membrane preparations from mammalian brain. Mol. Pharmacol. 12:1976;568-580.
77. Capsoni S., Ugolini G., Comparini A., Ruberti F., Berardi N., Cattaneo A. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6826-6831.
78. Capsoni S., Giannotta S., Cattaneo A. Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies. Mol. Cell. Neurosci. 21:2002;15-28.
79. Carli M., Robbins T.W., Evenden J.L., Everitt B.J. Effects of lesions to ascending noradrenergic neurones on performance of a 5-choice serial reaction task in rats; implications for theories of dorsal noradrenergic bundle function based on selective attention and arousal. Behav. Brain Res. 9:1983;361-380.
80. Carlsson A., Lindqvist M., Magnusson T. 3,4-Dihydroxy-phenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature. 180:1957;1200.
81. Carman L.S., Gage F.H., Shults C.W. Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior. Brain Res. 553:1991;275-283.
82. Carmignoto G., Canella R., Candeo P., Comelli M.C., Maffei L. Effects of nerve growth factor on neuronal plasticity of the kitten visual cortex. J. Physiol. 464:1993;343-360.
83. Carmignoto G., Pizzorusso T., Tia S., Vicini S. Brain-derived neurotrophic factor and nerve growth factor potentiate excitatory synaptic transmission in the rat visual cortex. J. Physiol. 498(Pt 1):1997;153-164.
84. Castren E., Pitkanen M., Sirvio J., Parsadanian A., Lindholm D., Thoenen H., Riekkinen P.J. The induction of LTP increases BDNF and NGF mRNA but decreases NT-3 mRNA in the dentate gyrus. NeuroReport. 4:1993;895-898.
85. Celesia G.G., Wanamaker W.M. Psychiatric disturbances in Parkinson's disease. Dis. Nerv. Syst. 33:1972;577-583.
86. Chadi G., Tinner B., Agnati L.F., Fuxe K. Basic fibroblast growth factor (bFGF, FGF-2) immunoreactivity exists in the noradrenaline, adrenaline and 5-HT nerve cells of the rat brain. Neurosci. Lett. 160:1993;171-176.
87. Chang H.T. Noradrenergic innervation of the substantia innominata: a light and electron microscopic analysis of dopamine beta-hydroxylase immunoreactive elements in the rat. Exp. Neurol. 104:1989;101-112.
88. Chan-Palay V. Alterations in the locus coeruleus in dementias of Alzheimer's and Parkinson's disease. Prog. Brain Res. 88:1991;625-630.
89. Chan-Palay V. Depression and senile dementia of the Alzheimer type: a role for moclobemide. Psychopharmacology (Berl.). 106:1992;S137-S139. (Suppl.).
90. Chan-Palay V., Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J. Comp. Neurol. 287:1989;373-392.
91. Chan-Palay V., Asan E. Quantitation of catecholamine neurons in the locus coeruleus in human brains of normal young and older adults and in depression. J. Comp. Neurol. 287:1989;357-372.
92. Chapleo C.B., Doxey J.C., Myers P.L., Roach A.G. RX 781094, a new potent, selective antagonist of alpha 2-adrenoceptors. Br. J. Pharmacol. 74:1981;. (842 pp.).
93. Chappell J., McMahan R., Chiba A., Gallagher M. A re-examination of the role of basal forebrain cholinergic neurons in spatial working memory. Neuropharmacology. 37:1998;481-487.
94. Chavez-Noriega L.E., Stevens C.F. Increased transmitter release at excitatory synapses produced by direct activation of adenylate cyclase in rat hippocampal slices. J. Neurosci. 14:1994;310-317.
95. Chen K.S., Tuszynski M.H., Gage F.H. Role of neurotrophic factors in Alzheimer's disease. Neurobiol. Aging. 10:1989;545-546.
96. Chopin P., Colpaert F.C., Marien M. Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J. Pharmacol. Exp. Ther. 288:1999;798-804.
97. Chopin P., Colpaert F.C., Marien M. Effects of acute and subchronic administration of dexefaroxan, an alpha(2)-adrenoceptor antagonist, on memory performance in young adult and aged rodents. J. Pharmacol. Exp. Ther. 301:2002;187-196.
98. Chopin P., Debeir T., Raisman-Vozari R., Colpaert F.C., Marien M. Protective effect of the alpha2-adrenoceptor antagonist, dexefaroxan, against spatial memory deficit induced by cortical devascularization in the adult rat. Exp. Neurol. 185:2003;198-200.
99. Cirelli C., Tononi G. Differential expression of plasticity-related genes in waking and sleep and their regulation by the noradrenergic system. J. Neurosci. 20:2000;9187-9194.
100. Clark W.G., Lipton J.M. Changes in body temperature after administration of adrenergic and serotonergic agents and related drugs including antidepressants: II. Neurosci. Biobehav. Rev. 10:1986;153-220.
101. Clark C.R., Geffen G.M., Geffen L.B. Catecholamines and the covert orientation of attention in humans. Neuropsychologia. 27:1989;131-139.
102. Collier T.J., Gash D.M., Sladek J.R. Jr. Transplantation of norepinephrine neurons into aged rats improves performance of a learned task. Brain Res. 448:1988;77-87.
103. Collingridge G.L., James T.A., MacLeod N.K. Neurochemical and electrophysiological evidence for a projection from the locus coeruleus to the substantia nigra [proceedings]. J. Physiol. 290:1979;. (44 pp.).
104. Colpaert F. Maximal magnitude of effect and potency of putative alpha-adrenoceptor agonists in causing CNS depression, in relaxing muscle, and in lowering body temperature. Drug Dev. Res. 7:1986;209-220.
105. Colpaert F.C. Effects of putative alpha-adrenoceptor antagonists and of other compounds on the loss of the righting reflex and on exophthalmia induced by xylazine in the rat. Drug Dev. Res. 7:1986;125-140.
106. Colpaert F. Pharmacological characteristics of tremor, rigidity and hypokinesia induce by reserpine in rat. Neuropharmacology. 26:1987;1431-1440.
107. Colpaert F. Noradrenergic mechanisms in Parkinson's disease: a theory. Briley M., Marien M. Noradrenergic Mechanisms in Parkinson's Disease. 1994;225-254 CRC Press, Boca Raton.
108. Colpaert F.C., Janssen P.A.J. Discriminative stimulus properties of xylazine in the rat: discriminability and effects of putative alpha-2 adrenoceptor agonists and antagonists. J. Pharmacol. Exp. Ther. 235:1985;521-527.
109. Conner J.M., Tuszynski M.H. Cholinergic lesions as a model of Alzheimer's disease. Emerich D., Dean R., Sanberg P. Central Nervous System Diseases. 2000;65-80 Humana Press, Totowa, NJ.
110. Connor B., Dragunow M. The role of neuronal growth factors in neurodegenerative disorders of the human brain. Brain Res. Brain Res. Rev. 27:1998;1-39.
111. Corbett D., Thornhill J. Temperature modulation (hypothermic and hyperthermic conditions) and its influence on histological and behavioral outcomes following cerebral ischemia. Brain Pathol. 10:2000;145-152.
112. Costall B., Naylor R.J. A comparison of circling models for the detection of antiparkinson activity. Psychopharmacologia. 41:1975;57-64.
113. Coull J.T. Alpha-2 adrenoceptors in the treatment of dementia: an attentional mechanism? J. Psychopharmacol. 10(Suppl. 3):1996;43-48.
114. Coull J.T., Middleton H.C., Robbins T.W., Sahakian B.J. Clonidine and diazepam have differential effects on tests of attention and learning. Psychopharmacology (Berl.). 120:1995;322-332.
115. Coull J.T., Sahakian B.J., Hodges J.R. The alpha(2) antagonist idazoxan remediates certain attentional and executive dysfunction in patients with dementia of frontal type. Psychopharmacology (Berl.). 123:1996;239-249.
116. Coyle J.T., Price D.L., DeLong M.R. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science. 219:1983;1184-1190.
117. Craik R.L., Hand P.J., Levin B.E. Locus coeruleus input affects glucose metabolism in activated rat barrel cortex. Brain Res. Bull. 19:1987;495-499.
118. Crisostomo E.A., Duncan P.W., Propst M., Dawson D.V., Davis J.N. Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients. Ann. Neurol. 23:1988;94-97.
119. Crook T., Wilner E., Rothwell A., Winterling D., McEntee W. Noradrenergic intervention in Alzheimer's disease. Psychopharmacol. Bull. 28:1992;67-70.
120. Crutcher K.A., Scott S.A., Liang S., Everson W.V., Weingartner J. Detection of NGF-like activity in human brain tissue: increased levels in Alzheimer's disease. J. Neurosci. 13:1993;2540-2550.
121. Cuello A.C., Garofalo L., Maysinger D., Ribeiro-da-Silva A. Neurotrophic factor-induced presynaptic morphological and functional changes of the cortical cholinergic input. Becker R., Giacobini E. Cholinergic Basis for Alzheimer Therapy. 1991;445-452 Birkhauser, Boston.
122. Dalrymple H.W., Hamilton C.A., Hannah J.A.M., Reid J.L. Cardiovascular effects of RX 781094 in the rabbit: possible partial agonist effect in addition to alpha-2 adrenoceptor antagonism. Br. J. Pharmacol. 78:1983;. (128 pp.).
123. Davies P., Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 2:1976;1403.
124. Davis J.N., Nishino K., Moore K. Noradrenergic regulation of delayed neuronal death after transient forebrain ischemia. Ginsberg M.D., Dietrich W.D. Cerebrovascular Diseases. 1989;109-115 Raven Press, New York.
125. Debeir T., Do P., Chopin P., Martel J.-C., Colpaert F., Marien M., Raisman R. Dexefaroxan, an alpha-2 adrenoceptor antagonist, protects against cortico-basalis cholinergic degeneration in the adult rat. Abstr. - Soc. Neurosci. 27:2001;1456.
126. Debeir T., Marien M., Chopin P., Martel J.C., Colpaert F., Raisman-Vozari R. Protective effects of the alpha 2-adrenoceptor antagonist, dexefaroxan, against degeneration of the basalocortical cholinergic system induced by cortical devascularization in the adult rat. Neuroscience. 115:2002;41-53.
127. Debeir T., Marien M., Rizk P., Colpaert F., Raisman R. Neuroprotection by the alpha2-adrenoceptor antagonist dexefaroxan (DEFX), against basocortical cholinergic degeneration in the adult rat may involve nerve growth factor (NGF). Abstracts from the 8th International Conference on Alzheimer's Disease and Related Disorders, 20-25 July 2002, Stockholm, Sweden. Neurobiol. Aging. vol. 23:2002;S532.
128. Decker M.W., Gallagher M. Scopolamine-disruption of radial arm maze performance: modification by noradrenergic depletion. Brain Res. 417:1987;59-69.
129. Decker M.W., McGaugh J.L. Effects of concurrent manipulations of cholinergic and noradrenergic function on learning and retention in mice. Brain Res. 477:1989;29-37.
130. Decker M.W., McGaugh J.L. The role of interactions between the cholinergic system and other neuromodulatory systems in learning and memory. Synapse. 7:1991;151-168.
131. Degryse A.D., Colpaert F.C. Symptoms and behavioral features induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in an old Java monkey [Macaca cynomolgus fascicularis (Raffles)]. Brain Res. Bull. 16:1986;561-571.
132. DeKosky S.T., Harbaugh R.E., Schmitt F.A., Bakay R.A., Chui H.C., Knopman D.S., Reeder T.M., Shetter A.G., Senter H.J., Markesbery W.R. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological, and cognitive correlations. Intraventricular Bethanecol Study Group. Ann. Neurol. 32:1992;625-632.
133. Delini-Stula A., Baumann P., Buch O. Depression of exploratory activity by clonidine in rats as a model for the detection of relative pre- and postsynaptic central noradrenergic receptor selectivity of alpha-adrenolytic drugs. Naunyn - Schmiedeberg's Arch. Pharmacol. 307:1979;115-122.
134. Dennis T., L'Heureux R., Carter C., Scatton B. Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. J. Pharmacol. Exp. Ther. 241:1987;642-649.
135. Devauges V., Sara S.J. Activation of the noradrenergic system facilitates an attentional shift in the rat. Behav. Brain Res. 39:1990;19-28.
136. Devauges V., Sara S.J. Memory retrieval enhancement by locus coeruleus stimulation: evidence for mediation by beta-receptors. Behav. Brain Res. 43:1991;93-97.
137. DeWitt D.A., Silver J. Regenerative failure: a potential mechanism for neuritic dystrophy in Alzheimer's disease. Exp. Neurol. 142:1996;103-110.
138. Dilsaver S.C., Minkus D., Swann A.C. Chronic treatment with valproate decreases the hypothermic response to clonidine. Pharmacol. Biochem. Behav. 45:1993;247-249.
139. Ditter S.M., Mirra S.S. Neuropathologic and clinical features of Parkinson's disease in Alzheimer's disease patients. Neurology. 37:1987;754-760.
140. Dolphin A., Adrien J., Hamon M., Bockaert J. Identity of [3H]-dihydroalprenolol binding sites and beta-adrenergic receptors coupled with adenylate cyclase in the central nervous system: pharmacological properties, distribution and adaptive responsiveness. Mol. Pharmacol. 15:1979;1-15.
141. Domino E.F., Ni L., Colpaert F., Marien M. Effects of (±) -idazoxan alone and in combination with L-DOPA methyl ester in MPTP-induced hemiparkinsonian monkeys. Recept. Channels. 9:2003;335-338.
142. Dooley D.J., Bittiger H., Hauser K.L., Bischoff S.F., Waldmeier P.C. Alteration of central alpha 2- and beta-adrenergic receptors in the rat after DSP-4, a selective noradrenergic neurotoxin. Neuroscience. 9:1983;889-898.
143. Dornan W.A., McCampbell A.R., Tinkler G.P., Hickman L.J., Bannon A.W., Decker M.W., Gunther K.L. Comparison of site-specific injections into the basal forebrain on water maze and radial arm maze performance in the male rat after immunolesioning with 192 IgG saporin. Behav. Brain Res. 82:1996;93-101.
144. Doxey J.C., Roach A.G., Strachan D.A., Virdee N.K. Selectivity and potency of 2-alkyl analogues of the alpha 2-adrenoceptor antagonist idazoxan (RX 781094) in peripheral systems. Br. J. Pharmacol. 83:1984;713-722.
145. Drew G.M., Gower A.J., Marriott A.S. Alpha 2-adrenoceptors mediate clonidine-induced sedation in the rat. Br. J. Pharmacol. 67:1979;133-141.
146. Dreyfus C.F. Neurotransmitters and neurotrophins collaborate to influence brain development. Perspect. Dev. Neurobiol. 5:1998;389-399.
147. Dringenberg H.C. Alzheimer's disease: more than a 'cholinergic disorder' - evidence that cholinergic-monoaminergic interactions contribute to EEG slowing and dementia. Behav. Brain Res. 115:2000;235-249.
148. Drouin C., Tassin J.-P. Norepinephrine. Ramachandran V.S. Encyclopedia of the Human Brain. vol. III:2002;625-646 Academic Press, San Diego.
149. Dubois B., Mayo W., Agid Y., Le Moal M., Simon H. Profound disturbances of spontaneous and learned behaviors following lesions of the nucleus basalis magnocellularis in the rat. Brain Res. 338:1985;249-258.
150. Dunnett S.B., Bjorklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature. 399(6378 Suppl.):1999;A32-A39.
151. Dunnett S.B., Everitt B.J., Robbins T.W. The basal forebrain-cortical cholinergic system: interpreting the functional consequences of excitotoxic lesions. Trends Neurosci. 14:1991;494-501.
152. Dunn-Meynell A.A., Yarlagadda Y., Levin B.E. Alpha 1-adrenoceptor blockade increases behavioral deficits in traumatic brain injury. J. Neurotrauma. 14:1997;43-52.
153. Dunwiddie T.V., Taylor M., Heginbotham L.R., Proctor W.R. Long-term increases in excitability in the CA1 region of rat hippocampus induced by beta-adrenergic stimulation: possible mediation by cAMP. J Neurosci. 12:1992;506-517.
154. Eddleston M., Mucke L. Molecular profile of reactive astrocytes - implications for their role in neurologic disease. Neuroscience. 54:1993;15-36.
155. Egan T.M., North R.A. Acetylcholine acts on m2-muscarinic receptors to excite rat locus coeruleus neurones. Br. J. Pharmacol. 85:1985;733-735.
156. Eisen A., Calne D. Amyotrophic lateral sclerosis, Parkinson's disease and Alzheimer's disease: phylogenetic disorders of the human neocortex sharing many characteristics. Can. J. Neurol. Sci. 19:1992;117-123.
157. Elliott P.J., Garofalo L., Cuello A.C. Limited neocortical devascularizing lesions causing deficits in memory retention and choline acetyltransferase activity - effects of the monosialoganglioside GM1. Neuroscience. 31:1989;63-76.
158. Engberg G., Svensson T.H. Pharmacological analysis of a cholinergic receptor mediated regulation of brain norepinephrine neurons. J. Neural Transm. 49:1980;137-150.
159. Engelborghs S., De Deyn P.P. The neurochemistry of Alzheimer's disease. Acta Neurol. Belg. 97:1997;67-84.
160. Farfel G.M., Seiden L.S. Role of hypothermia in the mechanism of protection against serotonergic toxicity: II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan. J. Pharmacol. Exp. Ther. 272:1995;868-875.
161. Fawcett J.P., Bamji S.X., Causing C.G., Aloyz R., Ase A.R., Reader T.A., McLean J.H., Miller F.D. Functional evidence that BDNF is an anterograde neuronal trophic factor in the CNS. J. Neurosci. 18:1998;2808-2821.
162. Fawcett J.P., Alonso-Vanegas M.A., Morris S.J., Miller F.D., Sadikot A.F., Murphy R.A. Evidence that brain-derived neurotrophic factor from presynaptic nerve terminals regulates the phenotype of calbindin-containing neurons in the lateral septum. J. Neurosci. 20:2000;274-282.
163. Feeney D.M. Mechanisms of noradrenergic modulation of physical therapy: effects on functional recovery after cortical injury. Goldstein L.B. Restorative Neurology: Advances in Pharmacotherapy for Recovery After Stroke. 1998;35-78 Futura Publishing, Armonk, NY.
164. Feeney D.M., Sutton R.L. Pharmacotherapy for recovery of function after brain injury. Crit. Rev. Neurobiol. 3:1987;135-197.
165. Feeney D.M., Westerberg V.S. Norepinephrine and brain damage: alpha noradrenergic pharmacology alters functional recovery after cortical trauma. Can. J. Psychol. 44:1990;233-252.
166. Feeney D.M., Gonzalez A., Law W.A. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science. 217:1982;855-857.
167. Feinstein D.L., Galea E., Reis D.J. Norepinephrine suppresses inducible nitric oxide synthase activity in rat astroglial cultures. J. Neurochem. 60:1993;1945-1948.
168. Feinstein D.L., Heneka M.T., Gavrilyuk V., Dello Russo C., Weinberg G., Galea E. Noradrenergic regulation of inflammatory gene expression in brain. Neurochem. Int. 41:2002;357-365.
169. Felten D.L., Hallman H., Jonsson G. Evidence for a neurotropic role of noradrenaline neurons in the postnatal development of rat cerebral cortex. J. Neurocytol. 11:1982;119-135.
170. Ferry B., McGaugh J.L. Clenbuterol administration into the basolateral amygdala post-training enhances retention in an inhibitory avoidance task. Neurobiol. Learn. Mem. 72:1999;8-12.
171. Ferry B., Roozendaal B., McGaugh J.L. Basolateral amygdala noradrenergic influences on memory storage are mediated by an interaction between beta- and alpha1-adrenoceptors. J. Neurosci. 19:1999;5119-5123.
172. Ferry B., Roozendaal B., McGaugh J.L. Involvement of alpha1- adrenoceptors in the basolateral amygdala in modulation of memory storage. Eur. J. Pharmacol. 372:1999;9-16.
173. Ferry B., Roozendaal B., McGaugh J.L. Role of norepinephrine in mediating stress hormone regulation of long-term memory storage: a critical involvement of the amygdala. Biol. Psychiatry. 46:1999;1140-1152.
174. Fibiger H.C. Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci. 14:1991;220-223.
175. Floyd R.A. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc. Soc. Exp. Biol. Med. 222:1999;236-245.
176. Folstein M.F., Bylsma F.W. Noncognitive symptoms of Alzheimer's disease. Terry R., Katzman R., Bick K. Alzheimer Disease. 1994;27-40 Raven Press, New York.
177. Foote S.L., Bloom F.E., Aston-Jones G. Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol. Rev. 63:1983;844-914.
178. Foote S.L., Berridge C.W., Adams L.M., Pineda J.A. Electrophysiological evidence for the involvement of the locus coeruleus in alerting, orienting, and attending. Prog. Brain Res. 88:1991;521-532.
179. Fornai F., Alessandri M.G., Fascetti F., Vaglini F., Corsini G.U. Clonidine suppresses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced reductions of striatal dopamine and tyrosine hydroxylase activity in mice. J. Neurochem. 65:1995;704-709.
180. Fornai F., Bassi L., Torracca M.T., Scalori V., Corsini G.U. Norepinephrine loss exacerbates methamphetamine-induced striatal dopamine depletion in mice. Eur. J. Pharmacol. 283:1995;99-102.
181. Fornai F., Bassi L., Torracca M.T., Alessandri M.G., Scalori V., Corsini G.U. Region- and neurotransmitter-dependent species and strain differences in DSP-4-induced monoamine depletion in rodents. Neurodegeneration. 5:1996;241-249.
182. Fornai F., Torracca M.T., Bassi L., D'Errigo D.A., Scalori V., Corsini G.U. Norepinephrine loss selectively enhances chronic nigrostriatal dopamine depletion in mice and rats. Brain Res. 735:1996;349-353.
183. Fornai F., Alessandri M.G., Torracca M.T., Bassi L., Corsini G.U. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions. J. Pharmacol. Exp. Ther. 283:1997;100-107.
184. Fornai F., Alessandri M.G., Torracca M.T., Bassi L., Scalori V., Corsini G.U. Noradrenergic modulation of methamphetamine-induced striatal dopamine depletion. Ann. N.Y. Acad. Sci. 844:1998;166-177.
185. Fornai F., Giorgi F.S., Alessandri M.G., Giusiani M., Corsini G.U. Effects of pretreatment with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) on methamphetamine pharmacokinetics and striatal dopamine losses. J. Neurochem. 72:1999;777-784.
186. Forstl H., Levy R., Burns A., Luthert P., Cairns N. Disproportionate loss of noradrenergic and cholinergic neurons as cause of depression in Alzheimer's disease - a hypothesis. Pharmacopsychiatry. 27:1994;11-15.
187. Fort P., Khateb A., Pegna A., Muhlethaler M., Jones B.E. Noradrenergic modulation of cholinergic nucleus basalis neurons demonstrated by in vitro pharmacological and immunohistochemical evidence in the guinea-pig brain. Eur. J. Neurosci. 7:1995;1502-1511.
188. Francis P.T., Cross A.J., Bowen D.M. Neurotransmitters and neuropeptides. Terry R., Katzman R., Bick K. Alzheimer Disease. 1994;247-261 Raven Press, New York.
189. Frey U., Morris R.G. Synaptic tagging and long-term potentiation. Nature. 385:1997;533-536.
190. Frey U., Huang Y.Y., Kandel E.R. Effects of cAMP simulate a late stage of LTP in hippocampal CA1 neurons. Science. 260:1993;1661-1664.
191. Freyaldenhoven T.E., Ali S.F. Role of heat shock proteins in MPTP-induced neurotoxicity. Ann. N.Y. Acad. Sci. 825:1997;167-178.
192. Friedman W.J., Ibanez C.F., Hallbook F., Persson H., Cain L.D., Dreyfus C.F., Black I.B. Differential actions of neurotrophins in the locus coeruleus and basal forebrain. Exp. Neurol. 119:1993;72-78.
193. Frith C.D., Dowdy J., Ferrier I.N., Crow T.J. Selective impairment of paired associate learning after administration of a centrally-acting adrenergic agonist (clonidine). Psychopharmacology (Berl.). 87:1985;490-493.
194. Fritschy J.M., Grzanna R. Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals. Neuroscience. 30:1989;181-197.
195. Fritschy J.M., Grzanna R. Distribution of locus coeruleus axons within the rat brainstem demonstrated by Phaseolus vulgaris leucoagglutinin anterograde tracing in combination with dopamine-beta-hydroxylase immunofluorescence. J. Comp. Neurol. 293:1990;616-631.
196. Fritschy J.M., Grzanna R. Selective effects of DSP-4 on locus coeruleus axons: are there pharmacologically different types of noradrenergic axons in the central nervous system? Prog. Brain Res. 88:1991;257-268.
197. Fritschy J.M., Grzanna R. Degeneration of rat locus coeruleus neurons is not accompanied by an irreversible loss of ascending projections. Evidence for reestablishment of forebrain innervation by surviving neurons. Ann. N.Y. Acad. Sci. 648:1992;275-278.
198. Fritschy J.M., Grzanna R. Restoration of ascending noradrenergic projections by residual locus coeruleus neurons: compensatory response to neurotoxin-induced cell death in the adult rat brain. J. Comp. Neurol. 321:1992;421-441.
199. Frohman E.M., Vayuvegula B., van den Noort S., Gupta S. Norepinephrine inhibits gamma-interferon-induced MHC class II (Ia) antigen expression on cultured brain astrocytes. J. Neuroimmunol. 17:1988;89-101.
200. Fujimoto S., Sasa M., Takaori S. Inhibition from locus coeruleus of caudate neurons activated by nigral stimulation. Brain Res. Bull. 6:1981;267-274.
201. Fuxe K., Agnati L. Two principal modes of electrochemical communication in the brain: volume versus wiring transmission. Fuxe K., Agnati L. Volume Transmission in the Brain. 1991;1-9 Raven Press, New York.
202. Gajdusek D.C. Hypothesis: interference with axonal transport of neurofilament as a common pathogenetic mechanism in certain diseases of the central nervous system. N. Engl. J. Med. 312:1985;714-719.
203. Garofalo L., Cuello A.C. Nerve growth factor and the monosialoganglioside GM1: analogous and different in vivo effects on biochemical, morphological, and behavioral parameters of adult cortically lesioned rats. Exp. Neurol. 125:1994;195-217.
204. Garofalo L., Ribeiro-da-Silva A., Cuello A.C. Nerve growth factor-induced synaptogenesis and hypertrophy of cortical cholinergic terminals. Proc. Natl. Acad. Sci. U. S. A. 89:1992;2639-2643.
205. Gaspar P. Anatomy of the noradrenergic pathways in the primate brain: alterations in Parkinson's disease. Briley M., Marien M. Noradrenergic Mechanisms in Parkinson's Disease. 1994;73-88 CRC Press, Boca Raton.
206. Gaspar P., Gray F. Parkinson's disease: a neuropathological study of 32 cases. Acta Neuropathol. (Berl.). 64:1984;43-52.
207. Gaspar P., Berger B., Alvarez C., Vigny A., Henry J.P. Catecholaminergic innervation of the septal area in man: immunocytochemical study using TH and DBH antibodies. J. Comp. Neurol. 241:1985;12-33.
208. Gaspar P., Stepniewska I., Kaas J.H. Topography and collateralization of the dopaminergic projections to motor and lateral prefrontal cortex in owl monkeys. J. Comp. Neurol. 325:1992;1-21.
209. Gavrilyuk V., Horvath P., Weinberg G., Feinstein D.L. A 27-bp region of the inducible nitric oxide synthase promoter regulates expression in glial cells. J. Neurochem. 78:2001;129-140.
210. Gerlach M., Riederer P., Przuntek H., Youdim M.B. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur. J. Pharmacol. 208:1991;273-286.
211. German D.C., Walker B.S., Manaye K., Smith W.K., Woodward D.J., North A.J. The human locus coeruleus: computer reconstruction of cellular distribution. J. Neurosci. 8:1988;1776-1788.
212. German D.C., Manaye K.F., White C.L. III, Woodward D.J., McIntire D.D., Smith W.K., Kalaria R.N., Mann D.M. Disease-specific patterns of locus coeruleus cell loss. Ann. Neurol. 32:1992;667-676.
213. Gesi M., Soldani P., Giorgi F.S., Santinami A., Bonaccorsi I., Fornai F. The role of the locus coeruleus in the development of Parkinson's disease. Neurosci. Biobehav. Rev. 24:2000;655-668.
214. Geula C., Mesulam M.M. Cortical cholinergic fibers in aging and Alzheimer's disease: a morphometric study. Neuroscience. 33:1989;469-481.
215. Geula C., Mesulam M. Cholinergic systems and related neuropathological predilection patterns in Alzheimer disease. Terry R., Katzman R., Bick K. Alzheimer Disease. 1994;263-291 Raven Press, New York.
216. Ghika J., Tennis M., Hoffman E., Schoenfeld D., Growdon J. Idazoxan treatment in progressive supranuclear palsy. Neurology. 41:1991;986-991.
217. Ghosh A., Carnahan J., Greenberg M.E. Requirement for BDNF in activity-dependent survival of cortical neurons. Science. 263:1994;1618-1623.
218. Gibb W.R., Luthert P.J., Marsden C.D. Corticobasal degeneration. Brain. 112:1989;1171-1192.
219. Gilmor M.L., Erickson J.D., Varoqui H., Hersh L.B., Bennett D.A., Cochran E.J., Mufson E.J., Levey A.I. Preservation of nucleus basalis neurons containing choline acetyltransferase and the vesicular acetylcholine transporter in the elderly with mild cognitive impairment and early Alzheimer's disease. J. Comp. Neurol. 411:1999;693-704.
220. Gladstone D.J., Black S.E. Enhancing recovery after stroke with noradrenergic pharmacotherapy: a new frontier? Can. J. Neurol. Sci. 27:2000;97-105.
221. Glowinski J., Iversen L.L. Regional studies of catecholamines in the rat brain: I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J. Neurochem. 13:1966;655-669.
222. Glue P., Sellman J.D., Joyce P.R., Nicholls M.G., Nutt D.J. The hypothermic response to clonidine is absent in alcohol withdrawal but returns in abstinence. Biol. Psychiatry. 24:1988;102-104.
223. Goldstein L.B. Effects of bilateral and unilateral locus coeruleus lesions on beam-walking recovery after subsequent unilateral sensorimotor cortex suction ablation in the rat. Restor. Neurol. Neurosci. 11:1997;55-63.
224. Goldstein L.B. Influence of common drugs and related factors on stroke outcome. Curr. Opin. Neurol. 10:1997;52-57.
225. Goldstein L.B. Potential effects of common drugs on stroke recovery. Arch. Neurol. 55:1998;454-456.
226. Goldstein L.B. Potential impact of drugs on poststroke motor recovery. Goldstein L.B. Restorative Neurology: Advances in Pharmacotherapy for Recovery After Stroke. 1998;241-256 Futura Publishing, Armonk, NY.
227. Goldstein L.B. Effects of amphetamines and small related molecules on recovery after stroke in animals and man. Neuropharmacology. 39:2000;852-859.
228. L.B. Goldstein, Amphetamine facilitated functional recovery after stroke. In: M.D. Ginsberg, W.D. Dietrich (Eds.), The 16th Princeton Conference on Cerebral Vascular Diseases, Raven Press, New York, pp. 303-308.
229. Goldstein L.B., Bullman S. Effects of dorsal noradrenergic bundle lesions on recovery after sensorimotor cortex injury. Pharmacol. Biochem. Behav. 58:1997;1151-1157.
230. Goldstein L.B., Davis J.N. Beam-walking in rats: studies towards developing an animal model of functional recovery after brain injury. J. Neurosci. Methods. 31:1990;101-107.
231. Goldstein L.B., Poe H., Davis J.N. An animal model of recovery of recovery of function after stroke: facilitation of recovery by an alpha-2 adrenergic receptor antagonist. Ann. Neurol. 26:1989;157. (Abstract).
232. Gomez-Mancilla B., Bedard P.J. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clin. Neuropharmacol. 16:1993;418-427.
233. Gonzalez M.M., Debilly G., Valatx J.L. Noradrenaline neurotoxin DSP-4 effects on sleep and brain temperature in the rat. Neurosci. Lett. 248:1998;93-96.
234. Gordon J.H., Shellenberger K. Regional catecholamine content in the rat brain: sex differences and correlation with motor activity. Neuropharmacology. 13:1974;129-137.
235. Gottfries C.G. Recognition and management of depression in the elderly. Int. Clin. Psychopharmacol. 12(Suppl. 7):1997;S31-S36.
236. Gould E., Gross C.G. Neurogenesis in adult mammals: some progress and problems. J. Neurosci. 22:2002;619-623.
237. Gould E., McEwen B.S., Tanapat P., Galea L.A., Fuchs E. Neurogenesis in the dentate gyrus of the adult tree shrew is regulated by psychosocial stress and NMDA receptor activation. J. Neurosci. 17:1997;2492-2498.
238. Grant J.A., Scrutton M.C. Interaction of selective alpha-adrenoceptor agonists and antagonists with human and rabbit blood platelets. Br. J. Pharmacol. 71:1980;121-134.
239. Grenhoff J., Svensson T.H. Clonidine regularizes substantia nigra dopamine cell firing. Life Sci. 42:1988;2003-2009.
240. Grenhoff J., Svensson T.H. Clonidine modulates dopamine cell firing in rat ventral tegmental area. Eur. J. Pharmacol. 165:1989;11-18.
241. Grenhoff J., Nisell M., Ferre S., Aston-Jones G., Svensson T.H. Noradrenergic modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the rat. J. Neural Transm. Gen. Sect. 93:1993;11-25.
242. Griffith R., Sutin J. Reactive astrocyte formation in vivo is regulated by noradrenergic axons. J. Comp. Neurol. 371:1996;362-375.
243. Grondin R., Hadj Tahar A., Doan V.D., Ladure P., Bedard P.J. Noradrenoceptor antagonism with idazoxan improves L-dopa-induced dyskinesias in MPTP monkeys. Naunyn-Schimiedeberg's Arch. Pharmacol. 361:2000;181-186.
244. Grzanna R., Berger U., Fritschy J.M., Geffard M. Acute action of DSP-4 on central norepinephrine axons: biochemical and immunohistochemical evidence for differential effects. J. Histochem. Cytochem. 37:1989;1435-1442.
245. Gu Q., Singer W. Effects of intracortical infusion of anticholinergic drugs on neuronal plasticity in kitten striate cortex. Eur. J. Neurosci. 5:1993;475-485.
246. Gustafson I., Miyauchi Y., Wieloch T.W. Postischemic administration of idazoxan, an alpha-2 adrenergic receptor antagonist, decreases neuronal damage in the rat brain. J. Cereb. Blood Flow Metab. 9:1989;171-174.
247. Gustafson I., Westerberg E., Wieloch T. Protection against ischemia-induced neuronal damage by the alpha 2-adrenoceptor antagonist idazoxan: influence of time of administration and possible mechanisms of action. J. Cereb. Blood Flow Metab. 10:1990;885-894.
248. Gybels J.M. Defining idiopathic Parkinson's disease. Briley M., Marien M. Noradrenergic Mechanisms in Parkinson's Disease. 1994;1-9 CRC Press, Boca Raton.
249. Haapalinna A., Sirvio J., Lammintausta R. Facilitation of cognitive functions by a specific alpha2-adrenoceptor antagonist, atipamezole. Eur. J. Pharmacol. 347:1998;29-40.
250. Haapalinna A., Sirvio J., MacDonald E., Virtanen R., Heinonen E. The effects of a specific alpha(2)-adrenoceptor antagonist, atipamezole, on cognitive performance and brain neurochemistry in aged Fisher 344 rats. Eur. J. Pharmacol. 387:2000;141-150.
251. Haapalinna A., Leino T., Heinonen E. The alpha(2)-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 368:2003;342-351.
252. Haeusler G. Clonidine-induced inhibition of sympathetic nerve activity: no indication for a central presynaptic or an indirect sympathomimetic mode of action. Naunyn-Schmiedeberg's Arch. Pharmacol. 286:1974;7-111.
253. Hagg T. Neurotrophins prevent death and differentially affect tyrosine hydroxylase of adult rat nigrostriatal neurons in vivo. Exp. Neurol. 149:1998;183-192.
254. Hakim A.M., Mathieson G. Dementia in Parkinson disease: a neuropathologic study. Neurology. 29:1979;1209-1214.
255. Halliday G.M., Li Y.W., Blumbergs P.C., Joh T.H., Cotton R.G., Howe P.R., Blessing W.W., Geffen L.B. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann. Neurol. 27:1990;373-385.
256. Halliday C.A., Jones B.J., Skingle M., Walsh D.M., Wise H., Tyers M.B. The pharmacology of fluparoxan: a selective alpha 2-adrenoceptor antagonist. Br. J. Pharmacol. 102:1991;887-895.
257. Handley S.L., Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn-Schmiedeberg's Arch. Pharmacol. 327:1984;1-5.
258. Hansson E., Ronnback L. Adrenergic receptor regulation of amino acid neurotransmitter uptake in astrocytes. Brain Res. Bull. 29:1992;297-301.
259. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 297:2002;353-356.
260. Harley C. Noradrenergic and locus coeruleus modulation of the perforant path-evoked potential in rat dentate gyrus supports a role for the locus coeruleus in attentional and memorial processes. Prog. Brain Res. 88:1991;307-321.
261. Haroutunian V., Santucci A.C., Davis K.L. Implications of multiple transmitter system lesions for cholinomimetic therapy in Alzheimer's disease. Prog. Brain Res. 84:1990;333-346.
262. Harro J., Pahkla R., Modiri A.R., Harro M., Kask A., Oreland L. Dose-dependent effects of noradrenergic denervation by DSP-4 treatment on forced swimming and beta-adrenoceptor binding in the rat. J. Neural Transm. 106:1999;619-629.
263. Hayes V.Y., Isackson P.J., Fabrazzo M., Follesa P., Mocchetti I. Induction of nerve growth factor and basic fibroblast growth factor mRNA following clenbuterol: contrasting anatomical and cellular localization. Exp. Neurol. 132:1995;33-41.
264. Hefti F. Is Alzheimer disease caused by lack of nerve growth factor? Ann. Neurol. 13:1983;109-110.
265. Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J. Neurosci. 6:1986;2155-2162.
266. Hefti F., Weiner W.J. Nerve growth factor and Alzheimer's disease. Ann. Neurol. 20:1986;275-281.
267. Heider M., Schliebs R., Rossner S., Bigl V. Basal forebrain cholinergic immunolesion by 192IgG-saporin: evidence for a presynaptic location of subpopulations of alpha 2- and beta-adrenergic as well as 5-HT2A receptors on cortical cholinergic terminals. Neurochem. Res. 22:1997;957-966.
268. Hellweg R., Gericke C.A., Jendroska K., Hartung H.D., Cervos-Navarro J. NGF content in the cerebral cortex of non-demented patients with amyloid-plaques and in symptomatic Alzheimer's disease. Int. J. Dev. Neurosci. 16:1998;787-794.
269. Henderson C.E., Bloch-Gallego E., Camu W., Gouin A., Lemeulle C., Mettling C. Motoneuron survival factors: biological roles and therapeutic potential. Neuromuscul. Disord. 3:1993;455-458.
270. Henderson C.E., Camu W., Mettling C., Gouin A., Poulsen K., Karihaloo M., Rullamas J., Evans T., McMahon S.B., Armanini M.P.et al. Neurotrophins promote motor neuron survival and are present in embryonic limb bud. Nature. 363:1993;266-270.
271. Heneka M.T., Galea E., Gavriluyk V., Dumitrescu-Ozimek L., Daeschner J., O'Banion M.K., Weinberg G., Klockgether T., Feinstein D.L. Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci. 22:2002;2434-2442.
272. Heneka M.T., Gavrilyuk V., Landreth G.E., O'Banion M.K., Weinberg G., Feinstein D.L. Noradrenergic depletion increases inflammatory responses in brain: effects on IkappaB and HSP70 expression. J. Neurochem. 85:2003;387-398.
273. Henry B., Fox S.H., Peggs D., Crossman A.R., Brotchie J.M. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov. Disord. 14:1999;744-753.
274. Hertz L. Is Alzheimer's disease an anterograde degeneration, originating in the brainstem, and disrupting metabolic and functional interactions between neurons and glial cells? Brain Res. Rev. 14:1989;335-353.
275. Hertz L. Autonomic control of neuronal-astrocytic interactions, regulating metabolic activities, and ion fluxes in the CNS. Brain Res. Bull. 29:1992;303-313.
276. Hiraga Y., Iwasaki T. Effects of cholinergic and monoaminergic antagonists and tranquilizers upon spatial memory in rats. Pharmacol. Biochem. Behav. 20:1984;205-207.
277. Honkanen A., Ingman K., Korpi E.R., Savola J.-M. JP 1730, a novel alpha2-adrenoceptor antagonist, enhances apomorphine- and L-dopa-induced circling behavior in the rat. Abstr. - Soc. Neurosci. 25:1999;1344.
278. Hoogendijk W.J., Pool C.W., Troost D., van Zwieten E., Swaab D.F. Image analyser-assisted morphometry of the locus coeruleus in Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis. Brain. 118(Pt. 1):1995;131-143.
279. Hopkins W.F., Johnston D. Noradrenergic enhancement of long-term potentiation at mossy fiber synapses in the hippocampus. J. Neurophysiol. 59:1988;667-687.
280. Horneykiewicz O., Pifl C. The validity of the MPTP primate model for the neurochemical pathology of idiopathic Parkinson's disease. Briley M., Marien M. Noradrenergic Mechanisms in Parkinson's Disease. 1994;11-23 CRC Press, Boca Raton.
281. Hu X.X., Goldmuntz E.A., Brosnan C.F. The effect of norepinephrine on endotoxin-mediated macrophage activation. J. Neuroimmunol. 31:1991;35-42.
282. Huang Y.Y., Kandel E.R. Modulation of both the early and the late phase of mossy fiber LTP by the activation of beta-adrenergic receptors. Neuron. 16:1996;611-617.
283. 3H]-RX821002: a highly selective ligand for the identification of alpha-2 adenoceptors in the rat brain. Mol. Neuropharmacol. 1:1992;219-229.
284. Hudson A.L., Robinson E.S., Lalies M.D., Tyacke R.J., Jackson H.C., Nutt D.J. In vitro and in vivo approaches to the characterization of the alpha2-adrenoceptor. J. Auton. Pharmacol. 19:1999;311-320.
285. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry. 55:1992;181-184.
286. Hughes Z.A., Stanford S.C. A partial noradrenergic lesion induced by DSP-4 increases extracellular noradrenaline concentration in rat frontal cortex: a microdialysis study in vivo. Psychopharmacology (Berl.). 136:1998;299-303.
287. Hulette C., Mirra S., Wilkinson W., Heyman A., Fillenbaum G., Clark C. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part IX. A prospective cliniconeuropathologic study of Parkinson's features in Alzheimer's disease. Neurology. 45:1995;1991-1995.
288. Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., Lindsay R.M. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature. 350:1991;230-232.
289. Imamura K., Kasamatsu T. Ocular dominance plasticity restored by NA infusion to aplastic visual cortex of anesthetized and paralyzed kittens. Exp. Brain Res. 87:1991;309-318.
290. Imamura K., Kasamatsu T., Shirokawa T., Ohashi T. Restoration of ocular dominance plasticity mediated by adenosine 3',5'-monophosphate in adult visual cortex. Proc. R. Soc. Lond., B Biol. Sci. 266:1999;1507-1516.
291. Ip N.Y., Stitt T.N., Tapley P., Klein R., Glass D.J., Fandl J., Greene L.A., Barbacid M., Yancopoulos G.D. Similarities and differences in the way neurotrophins interact with the Trk receptors in neuronal and nonneuronal cells. Neuron. 10:1993;137-149.
292. Izumi Y., Zorumski C.F. Norepinephrine promotes long-term potentiation in the adult rat hippocampus in vitro. Synapse. 31:1999;196-202.
293. Jaim-Etcheverry G. 2-Chloroethylamines (DSP-4 and Xylamine). Kostrzewa R.M. Highly Selective Neurotoxins: Basic and Clincial Applications. 1998;131-140 Humana Press, Totowa, NJ.
294. Jakala P., Sirvio J., Riekkinen P. Jr., Haapalanna A., Riekkinen P. Effects of atipamezole, an alpha 2-adrenoceptor antagonist, on the performance of rats in a five-choice serial reaction time task. Pharmacol. Biochem. Behav. 42:1992;903-907.
295. Jakala P., Riekkinen M., Sirvio J., Koivisto E., Kejonen K., Vanhanen M., Riekkinen P. Jr. Guanfacine, but not clonidine, improves planning and working memory performance in humans. Neuropsychopharmacology. 20:1999;460-470.
296. Jakala P., Riekkinen M., Sirvio J., Koivisto E., Riekkinen P. Jr. Clonidine, but not guanfacine, impairs choice reaction time performance in young healthy volunteers. Neuropsychopharmacology. 21:1999;495-502.
297. Jakala P., Sirvio J., Riekkinen M., Koivisto E., Kejonen K., Vanhanen M., Riekkinen P. Jr. Guanfacine and clonidine, alpha 2-agonists, improve paired associates learning, but not delayed matching to sample, in humans. Neuropsychopharmacology. 20:1999;119-130.
298. Jankovic J., Talosa E. Parkinson's Disease and Movement Disorders. 1988;Urban and Schwartzenberg, Baltimore. 499 pp.
299. Jellinger K., Bancher C. Neuropathology. Litvan I., Agid Y. Progressive Supranuclear Palsy, Clincial and Research Approaches. 1992;44-88 Oxford Univ. Press, New York.
300. Johnson J.E., Barde Y.A., Schwab M., Thoenen H. Brain-derived neurotrophic factor supports the survival of cultured rat retinal ganglion cells. J. Neurosci. 6:1986;3031-3038.
301. Jolkkonen J., Puurunen K., Rantakomi S., Harkonen A., Haapalinna A., Sivenius J. Behavioral effects of the alpha(2)-adrenoceptor antagonist, atipamezole, after focal cerebral ischemia in rats. Eur. J. Pharmacol. 400:2000;211-219.
302. Jones B.E., Moore R.Y. Ascending projections of the locus coeruleus in the rat. II: Autoradiographic study. Brain Res. 127:1977;25-53.
303. Jones B.E., Yang T.Z. The efferent projections from the reticular formation and the locus coeruleus studied by anterograde and retrograde axonal transport in the rat. J. Comp. Neurol. 242:1985;56-92.
304. Jonsson G., Wiesel F.A., Hallman H. Developmental plasticity of central noradrenaline neurons after neonatal damage-changes in transmitter functions. J. Neurobiol. 10:1979;337-353.
305. Jonsson G., Hallman H., Ponzio F., Ross S. DSP4 (N-(2-chloroethyl)-N- ethyl-2-bromobenzylamine) - a useful denervation tool for central and peripheral noradrenaline neurons. Eur. J. Pharmacol. 72:1981;173-188.
306. Kalsner S. Autoreceptors do not regulate routinely neurotransmitter release: focus on adrenergic systems. J. Neurochem. 78:2001;676-684.
307. Kasamatsu T. Norepinephrine hypothesis for visual cortical plasticity: thesis, antithesis, and recent development. Curr. Top. Dev. Biol. 21:1987;367-389.
308. Kasamatsu T. Adrenergic regulation of visuocortical plasticity: a role of the locus coeruleus system. Prog. Brain Res. 88:1991;599-616.
309. Kasamatsu T., Watabe K., Heggelund P., Scholler E. Plasticity in cat visual cortex restored by electrical stimulation of the locus coeruleus. Neurosci. Res. 2:1985;365-386.
310. Kask A., Harro J., Tuomaine P., Rago L., Mannisto P.T. Overflow of noradrenaline and dopamine in frontal cortex after [N-(2-chloroethyl)-N-ethyl-2- bromobenzylamine] (DSP-4) treatment: in vivo microdialysis study in anaesthetized rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:1997;267-272.
311. Katsuki H., Izumi Y., Zorumski C.F. Noradrenergic regulation of synaptic plasticity in the hippocampal CA1 region. J. Neurophysiol. 77:1997;3013-3020.
312. Katzman R., Kawas C. The epidemiology of dementia and Alzheimer's disease. Terry R., Katzman R., Bick K. Alzheimer Disease. 1994;105-122 Raven Press, New York.
313. Khachaturian Z., Mesulam M. Alzheimer's Disease - A Compendium of Current Theories. Ann. N.Y. Acad. Sci. vol. 294:2000;1-195.
314. Kikuchi K., Nishino K., Ohyu H. Increasing CNS norepinephrine levels by the precursor L-DOPS facilitates beam-walking recovery after sensorimotor cortex ablation in rats. Brain Res. 860:2000;130-135.
315. Kilbourn M.R., Sherman P., Abbott L.C. Reduced MPTP neurotoxicity in striatum of the mutant mouse tottering. Synapse. 30:1998;205-210.
316. Kiprianova I., Sandkuhler J., Schwab S., Hoyer S., Spranger M. Brain-derived neurotrophic factor improves long-term potentiation and cognitive functions after transient forebrain ischemia in the rat. Exp. Neurol. 159:1999;511-519.
317. Kirkwood A., Rozas C., Kirkwood J., Perez F., Bear M.F. Modulation of long-term synaptic depression in visual cortex by acetylcholine and norepinephrine. J. Neurosci. 19:1999;1599-1609.
318. Knipper M., Rylett R.J. A new twist in an old story: the role for crosstalk of neuronal and trophic activity. Neurochem. Int. 31:1997;659-676.
319. Knipper M., Beck A., Rylett J., Breer H. Neurotrophin induced second messenger responses in rat brain synaptosomes. NeuroReport. 4:1993;483-486.
320. Knipper M., da Penha Berzaghi M., Blochl A., Breer H., Thoenen H., Lindholm D. Positive feedback between acetylcholine and the neurotrophins nerve growth factor and brain-derived neurotrophic factor in the rat hippocampus. Eur. J. Neurosci. 6:1994;668-671.
321. Knusel B., Beck K.D., Winslow J.W., Rosenthal A., Burton L.E., Widmer H.R., Nikolics K., Hefti F. Brain-derived neurotrophic factor administration protects basal forebrain cholinergic but not nigral dopaminergic neurons from degenerative changes after axotomy in the adult rat brain. J. Neurosci. 12:1992;4391-4402.
322. Koda L.Y., Schulman J.A., Bloom F.E. Ultrastructural identification of noradrenergic terminals in rat hippocampus: unilateral destruction of the locus coeruleus with 6-hydroxydopamine. Brain Res. 145:1978;190-195.
323. Kokubo Y., Kuzuhara S., Narita Y. Geographical distribution of amyotrophic lateral sclerosis with neurofibrillary tangles in the Kii Peninsula of Japan. J. Neurol. 247:2000;850-852.
324. Kolb B., Sutherland R.J. Noradrenaline depletion blocks behavioral sparing and alters cortical morphogenesis after neonatal frontal cortex damage in rats. J. Neurosci. 12:1992;2321-2330.
325. Kolb B., Cote S., Ribeiro-da-Silva A., Cuello A.C. Nerve growth factor treatment prevents dendritic atrophy and promotes recovery of function after cortical injury. Neuroscience. 76:1997;1139-1151.
326. Kolb B., Stewart J., Sutherland R.J. Recovery of function is associated with increased spine density in cortical pyramidal cells after frontal lesions and/or noradrenaline depletion in neonatal rats. Behav. Brain Res. 89:1997;61-70.
327. Kopin I.J. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol. Rev. 37:1985;333-364.
328. Korsching S., Auburger G., Heumann R., Scott J., Thoenen H. Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation. EMBO J. 4:1985;1389-1393.
329. Korte M., Staiger V., Griesbeck O., Thoenen H., Bonhoeffer T. The involvement of brain-derived neurotrophic factor in hippocampal long-term potentiation revealed by gene targeting experiments. J. Physiol. (Paris). 90:1996;157-164.
330. Kromer L.F. Nerve growth factor treatment after brain injury prevents neuronal death. Science. 235:1987;214-216.
331. Kruglikov R. On the interaction of neurotransmitter systems in the processes of learning and memory. Marsan C., Matthies H. Neuronal Plasticity and Memory Formation. 1982;339-351 Raven Press, New York.
332. Kulkarni V.A., Jha S., Vaidya V.A. Depletion of norepinephrine decreases the proliferation, but does not influence the survival and differentiation, of granule cell progenitors in the adult rat hippocampus. Eur. J. Neurosci. 16:2002;2008-2012.
333. Kwon J.H., Eves E.M., Farrell S., Segovia J., Tobin A.J., Wainer B.H., Downen M. Beta-adrenergic receptor activation promotes process outgrowth in an embryonic rat basal forebrain cell line and in primary neurons. Eur. J. Neurosci. 8:1996;2042-2055.
334. Laifenfeld D., Klein E., Ben-Shachar D. Norepinephrine alters the expression of genes involved in neuronal sprouting and differentiation: relevance for major depression and antidepressant mechanisms. J. Neurochem. 83:2002;1054-1064.
335. Langston J.W. Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Ann. Neurol. 44:1998;S45-S52.
336. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 219:1983;979-980.
337. Lategan A.J., Marien M.R., Colpaert F.C. Effects of locus coeruleus lesions on the release of endogenous dopamine in the rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. Brain Res. 523:1990;134-138.
338. Lategan A., Marien M., Colpaert F. Suppression of nigrostriatal and mesolimbic dopamine release in vivo following noradrenaline depletion by DSP-4: a microdialysis study. Life Sci. 50:1992;995-999.
339. Lefkowitz R.J., Hoffman B.B., Taylor P. The autonomic and somatic motor nervous systems. Hardman J.G., Limbird L.E. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 1996;105-139 McGraw-Hill, New York.
340. Leverenz J., Sumi S.M. Parkinson's disease in patients with Alzheimer's disease. Arch. Neurol. 43:1986;662-664.
341. Levin B.E., Craik R.L., Hand P.J. The role of norepinephrine in adult rat somatosensory (SmI) cortical metabolism and plasticity. Brain Res. 443:1988;261-271.
342. Levitt P., Moore R.Y. Development of the noradrenergic innervation of neocortex. Brain Res. 162:1979;243-259.
343. Lin R.Z., Chen J., Hu Z.W., Hoffman B.B. Phosphorylation of the cAMP response element-binding protein and activation of transcription by alpha1 adrenergic receptors. J. Biol. Chem. 273:1998;30033-30038.
344. Lindner M.D. Reliability, distribution, and validity of age-related cognitive deficits in the Morris water maze. Neurobiol. Learn. Mem. 68:1997;203-220.
345. Lindsay R.M., Peters C. Spinal cord contains neurotrophic activity for spinal nerve sensory neurons. Late developmental appearance of a survival factor distinct from nerve growth factor. Neuroscience. 12:1984;45-51.
346. Lindsay R.M., Barde Y.A., Davies A.M., Rohrer H. Differences and similarities in the neurotrophic growth factor requirements of sensory neurons derived from neural crest and neural placode. J. Cell. Sci. (Suppl. 3):1985;115-129.
347. Lindvall O., Stenevi U. Dopamine and noradrenaline neurons projecting to the septal area in the rat. Cell Tissue Res. 190:1978;383-407.
348. Linnarsson S., Bjorklund A., Ernfors P. Learning deficit in BDNF mutant mice. Eur. J. Neurosci. 9:1997;2581-2587.
349. Llado J., Esteban S., Garcia-Sevilla J.A. The alpha 2-adrenoceptor antagonist idazoxan is an agonist at 5-HT1A autoreceptors modulating serotonin synthesis in the rat brain in vivo. Neurosci. Lett. 218:1996;111-114.
350. Loeb E.P., Chang F.F., Greenough W.T. Effects of neonatal 6-hydroxydopamine treatment upon morphological organization of the posteromedial barrel subfield in mouse somatosensory cortex. Brain Res. 403:1987;113-120.
351. Lohr J.B., Jeste D.V. Locus ceruleus morphometry in aging and schizophrenia. Acta Psychiatr. Scand. 77:1988;689-697.
352. Lu B., Yokoyama M., Dreyfus C.F., Black I.B. NGF gene expression in actively growing brain glia. J. Neurosci. 11:1991;318-326.
353. Lyness S.A., Zarow C., Chui H.C. Neuron loss in key cholinergic and aminergic nuclei in Alzheimer disease: a meta-analysis. Neurobiol. Aging. 24:2003;1-23.
354. Madden K.S., Sanders V.M., Felten D.L. Catecholamine influences and sympathetic neural modulation of immune responsiveness. Annu. Rev. Pharmacol. Toxicol. 35:1995;417-448.
355. Maeda T., Toyama M., Shimizu N. Modification of postnatal development of neocortex in rat brain with experimental deprivation of locus coeruleus. Brain Res. 70:1974;515-520.
356. Mamounas L.A., Blue M.E., Siuciak J.A., Altar C.A. Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J. Neurosci. 15:1995;7929-7939.
357. Mann D. The locus coeruleus and its possible role in ageing and degenerative disease of the human central nervous system. Mech. Ageing Dev. 23:1983;73-94.
358. Mann D.M. Subcortical afferent projection systems in Huntington's chorea. Acta Neuropathol. (Berl.). 78:1989;551-554.
359. Mann D.M., Yates P.O. Dementia and cerebral noradrenergic innervation. Br. Med. J. (Clin. Res. Ed.). 282:1981;474-475.
360. Mann D.M., Lincoln J., Yates P.O., Stamp J.E., Toper S. Changes in the monoamine containing neurones of the human CNS in senile dementia. Br. J. Psychiatry. 136:1980;533-541.
361. Mann D.M., Yates P.O., Hawkes J. The noradrenergic system in Alzheimer and multi-infarct dementias. J. Neurol. Neurosurg. Psychiatry. 45:1982;113-119.
362. Mann D.M., Yates P.O., Hawkes J. The pathology of the human locus ceruleus. Clin. Neuropathol. 2:1983;1-7.
363. Manson A.J., Iakovidou E., Lees A.J. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Mov. Disord. 15:2000;336-337.
364. Marcyniuk B., Mann D.M., Yates P.O., Ravindra C.R. Topography of nerve cell loss from the locus caeruleus in middle aged persons with Down's syndrome. J. Neurol. Sci. 83:1988;15-24.
365. Marien M., Cosi C. Central noradrenergic neurotoxicity of DSP4 in mice. Studies on the neuroprotective potential of the poly(ADP-ribose) polymerase inhibitor, benzamide. Ann. N.Y. Acad. Sci. 890:1999;336-339.
366. Marien M., Briley M., Colpaert F. Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur. J. Pharmacol. 236:1993;487-489.
367. Marien M., Lategan A., Colpaert F. Noradrenergic control of striatal dopamine release. Briley M., Marien M. Noradrenergic Mechanisms in Parkinson's Disease. 1994;139-158 CRC Press, Boca Raton.
368. Marsh G.G., Markham C.H. Does levodopa alter depression and psychopathology in Parkinsonism patients? J. Neurol. Neurosurg. Psychiatry. 36:1973;925-935.
369. Martel J.-C., Chopin P., Colpaert F., Marien M. Neuroprotective effects of the alpha2-adrenoceptor antagonists, (+)-efaroxan and (+/-)-idazoxan, against quinolinic acid-induced lesions of the rat striatum. Exp. Neurol. 154:1998;595-601.
370. Marx F., Blasko I., Pavelka M., Grubeck-Loebenstein B. The possible role of the immune system in Alzheimer's disease. Exp. Gerontol. 33:1998;871-881.
371. Mason S.T., Fibiger H.C. Regional topography within noradrenergic locus coeruleus as revealed by retrograde transport of horseradish peroxidase. J. Comp. Neurol. 187:1979;703-724.
372. Mavridis M., Colpaert F.C., Millan M.J. Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigra-lesioned rats by alpha 1 as compared to alpha 2 agonists and antagonists. Brain Res. 562:1991;216-224.
373. Mavridis M., Degryse A.D., Lategan A., Marien M., Colpaert F. Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. Neuroscience. 41:1991;507-523.
374. Mayeux R., Denaro J., Hemenegildo N., Marder K., Tang M.X., Cote L.J., Stern Y. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch. Neurol. 49:1992;492-497.
375. McEntee W.J., Crook T.H., Jenkyn L.R., Petrie W., Larrabee G.J., Coffey D.J. Treatment of age-associated memory impairment with guanfacine. Psychopharmacol. Bull. 27:1991;41-46.
376. McGaugh J.L. Involvement of hormonal and neuromodulatory systems in the regulation of memory storage. Annu. Rev. Neurosci. 12:1989;255-287.
377. McGeer P.L., McGeer E.G. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res. Brain Res. Rev. 21:1995;195-218.
378. McGeer E.G., McGeer P.L. Brain inflammation in Alzheimer disease and the therapeutic implications. Curr. Pharm. Des. 5:1999;821-836.
379. McGeer E., Ling G., McGeer P. Conversion of tyrosine to catecholamines by cat brain in vivo. Biochem. Biophys. Res. Commun. 13:1963;291-296.
380. Medgett I.C., McCulloch M.W., Rand M.J. Partial agonist of clonidine on prejunctional and postjunctional alpha-adrenoceptors. Naunyn-Schmiedeberg's. Arch. Pharmacol. 304:1978;215-221.
381. Mesulam M.M. The systems-level organization of cholinergic innervation in the human cerebral cortex and its alterations in Alzheimer's disease. Prog. Brain Res. 109:1996;285-297.
382. M'Harzi M., Willig F., Bardelay C., Palou A.M., Oberlander C. Effects of RU 52583, an alpha 2-antagonist, on memory in rats with excitotoxic damage to the septal area. Pharmacol. Biochem. Behav. 56:1997;649-655.
383. Michel M.C., Ernsberger P. Keeping an eye on the I site: imidazoline-preferring receptors. Trends Pharmacol. Sci. 13:1992;369-370.
384. Michel M.C., Insel P.A. Are there multiple imidazoline binding sites? Trends Pharmacol. Sci. 10:1989;342-344.
385. Millan M.J., Bervoets K., Rivet J.M., Widdowson P., Renouard A., Le Marouille-Girardon S., Gobert A. Multiple alpha-2 adrenergic receptor subtypes. II. Evidence for a role of rat R alpha-2A adrenergic receptors in the control of nociception, motor behavior and hippocampal synthesis of noradrenaline. J. Pharmacol. Exp. Ther. 270:1994;958-972.
386. Mizutani T. Neuropathological background of spinocerebellar degeneration-with special reference to autonomic nervous system lesions in olivopontocerebellar atrophy, Shy-Drager syndrome and multiple system atrophy. No To Shinkei. 37:1985;675-685.
387. Mocchetti I., De Bernardi M.A., Fabrazzo M. Towards the pharmacological regulation of nerve growth factor biosynthesis. Becker R., Giacobini E. Cholinergic Basis for Alzheimer Therapy. 1991;451-459 Birkhauser, Boston.
388. Mohr E., Schlegel J., Fabbrini G., Williams J., Mouradian M.M., Mann U.M., Claus J.J., Fedio P., Chase T.N. Clonidine treatment of Alzheimer's disease. Arch. Neurol. 46:1989;376-378.
389. Molderings G.J., Schmidt K., Bonisch H., Gothert M. Inhibition of 5-HT3 receptor function by imidazolines in mouse neuroblastoma cells: potential involvement of sigma 2 binding sites. Naunyn-Schmiedeberg's Arch. Pharmacol. 354:1996;245-252.
390. Moore R.Y., Bloom F.E. Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. Annu. Rev. Neurosci. 2:1979;113-168.
391. Mori K., Ozaki E., Zhang B., Yang L., Yokoyama A., Takeda I., Maeda N., Sakanaka M., Tanaka J. Effects of norepinephrine on rat cultured microglial cells that express alpha1, alpha2, beta1 and beta2 adrenergic receptors. Neuropharmacology. 43:2002;1026-1034.
392. Moroni F., Tanganelli S., Antonelli T., Carla V., Bianchi C., Beani L. Modulation of cortical acetylcholine and gamma-aminobutyric acid release in freely moving guinea pigs: effects of clonidine and other adrenergic drugs. J. Pharmacol. Exp. Ther. 227:1983;435-440.
393. Morris J.C., Drazner M., Fulling K., Grant E.A., Goldring J. Clinical and pathological aspects of parkinsonism in Alzheimer's disease. A role for extranigral factors? Arch. Neurol. 46:1989;651-657.
394. Morrison B.M., Hof P.R., Morrison J.H. Determinants of neuronal vulnerability in neurodegenerative diseases. Ann. Neurol. 44:1998;S32-S44.
395. Morse J.K., Wiegand S.J., Anderson K., You Y., Cai N., Carnahan J., Miller J., DiStefano P.S., Altar C.A., Lindsay R.M. Brain-derived neurotrophic factor (BDNF) prevents the degeneration of medial septal cholinergic neurons following fimbria transection. J. Neurosci. 13:1993;4146-4156.
396. Moy L.Y., Albers D.S., Sonsalla P.K. Lowering ambient or core body temperature elevates striatal MPP+ levels and enhances toxicity to dopamine neurons in MPTP-treated mice. Brain Res. 790:1998;264-269.
397. Mufson E.J., Conner J.M., Varon S., Kordower J.H. Nerve growth factor-like immunoreactive profiles in the primate basal forebrain and hippocampal formation. J. Comp. Neurol. 341:1994;507-519.
398. Mufson E.J., Kroin J.S., Sendera T.J., Sobreviela T. Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog. Neurobiol. 57:1999;451-484.
399. Mufson E.J., Ma S.Y., Cochran E.J., Bennett D.A., Beckett L.A., Jaffar S., Saragovi H.U., Kordower J.H. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J. Comp. Neurol. 427:2000;19-30.
400. Naqui S.Z., Harris B.S., Thomaidou D., Parnavelas J.G. The noradrenergic system influences the fate of Cajal-Retzius cells in the developing cerebral cortex. Brain Res. Dev. Brain Res. 113:1999;75-82.
401. Narabayashi H., Kondo T., Nagatsu T., Hayashi A., Suzuki T. DL-threo-3,4-Dihydroxyphenylserine for freezing symptom in parkinsonism. Adv. Neurol. 40:1984;497-502.
402. Narabayashi H., Yokochi F., Ogawa T., Igakura T. Analysis of L-threo-3,4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease. No To Shinkei. 43:1991;263-268.
403. Neill D. Alzheimer's disease: maladaptive synaptoplasticity hypothesis. Neurodegeneration. 4:1995;217-232.
404. Newman-Tancredi A.E., Nicolas J.P., Audinot V., Gavaudan S., Verriele L., Touzard M., Chaput C., Richard N., Millan M.J. Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 358:1998;197-206.
405. Nieto-Sampedro M., Lewis E.R., Cotman C.W., Manthorpe M., Skaper S.D., Barbin G., Longo F.M., Varon S. Brain injury causes a time-dependent increase in neuronotrophic activity at the lesion site. Science. 217:1982;860-861.
406. Nishi K., Kondo T., Narabayashi H. Destruction of norepinephrine terminals in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice reduces locomotor activity induced by L-dopa. Neurosci. Lett. 123:1991;244-247.
407. Nitsch R.M. From acetylcholine to amyloid: neurotransmitters and the pathology of Alzheimer's disease. Neurodegeneration. 5:1996;477-482.
408. Nitsch R.M., Slack B.E., Farber S.A., Schulz J.G., Deng M., Kim C., Borghesani P.R., Korver W., Wurtman R.J., Growdon J.H. Regulation of proteolytic processing of the amyloid beta-protein precursor of Alzheimer's disease in transfected cell lines and in brain slices. J. Neural Transm. (Suppl. 44):1994;21-27.
409. Nitsch R.M., Wurtman R.J., Growdon J. Regulation of APP processing. Potential for the therapeutical reduction of brain amyloid burden. Ann. N.Y. Acad. Sci. 777:1996;175-182.
410. Nieuwenhuys R. Chemoarchitecture of the Brain. 1984;Springer-Verlag, Berlin. 246 pp.
411. Nutt D., Lalies M., Hudson A. The effects of alpha-2 adrenoceptor antagonists on extracellular dopamine concentrations in rat striatum. Briley M., Marien M. Noradrenergic Mechanisms in Parkinson's Disease. 1994;159-172 CRC Press, Boca Raton.
412. Ohno M., Yamamoto T., Kobayashi M., Watanabe S. Impairment of working memory induced by scopolamine in rats with noradrenergic DSP-4 lesions. Eur. J. Pharmacol. 238:1993;117-120.
413. Ohno M., Yoshimatsu A., Kobayashi M., Watanabe S. Noradrenergic DSP-4 lesions aggravate impairment of working memory produced by hippocampal muscarinic blockade in rats. Pharmacol. Biochem. Behav. 57:1997;257-261.
414. Oke A.F., Adams R.N. Selective attention dysfunctions in adult rats neonatally treated with 6-hydoxydopamine. Pharmacol. Biochem. Behav. 9:1978;429-432.
415. Olanow C.W. Free radicals and neurodegeneration. Trends Neurosci. 16:1993;439-444.
416. Olpe H.R., Steinmann M. Responses of locus coeruleus neurons to neuropeptides. Prog. Brain Res. 88:1991;241-248.
417. Orrell R.W., King A.W., Hilton D.A., Campbell M.J., Lane R.J., de Belleroche J.S. Familial amyotrophic lateral sclerosis with a point mutation of SOD-1: intrafamilial heterogeneity of disease duration associated with neurofibrillary tangles. J. Neurol. Neurosurg. Psychiatry. 59:1995;266-270.
418. Page K.J., Everitt B.J., Robbins T.W., Marston H.M., Wilkinson L.S. Dissociable effects on spatial maze and passive avoidance acquisition and retention following AMPA- and ibotenic acid-induced excitotoxic lesions of the basal forebrain in rats: differential dependence on cholinergic neuronal loss. Neuroscience. 43:1991;457-472.
419. Palmer A.M., Gershon S. Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? FASEB J. 4:1990;2745-2752.
420. Parent A. Extrinsic connections of the basal ganglia. Trends Neurosci. 13:1990;254-258.
421. Parnavelas J.G., Papadopoulos G.C. The monoaminergic innervation of the cerebral cortex is not diffuse and nonspecific. Trends Neurosci. 12:1989;315-319.
422. Patterson S.L., Grover L.M., Schwartzkroin P.A., Bothwell M. Neurotrophin expression in rat hippocampal slices: a stimulus paradigm inducing LTP in CA1 evokes increases in BDNF and NT-3 mRNAs. Neuron. 9:1992;1081-1088.
423. Pauwels P.J., Tardif S., Wurch T., Colpaert F.C. Facilitation of constitutive alpha(2A)-adrenoceptor activity by both single amino acid mutation (Thr(373)Lys) and g(alphao) protein coexpression: evidence for inverse agonism. J. Pharmacol. Exp. Ther. 292:2000;654-663.
424. Perl D.P., Olanow C.W., Calne D. Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration? Ann. Neurol. 44(3 Suppl. 1):1998;S19-S31.
425. Perry E.K. The cholinergic system in old age and Alzheimer's disease. Age Ageing. 9:1980;1-8.
426. Phillips H.S., Hains J.M., Armanini M., Laramee G.R., Johnson S.A., Winslow J.W. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron. 7:1991;695-702.
427. Phillipson O.T. Afferent projections to the ventral tegmental area of Tsai and interfascicular nucleus: a horseradish peroxidase study in the rat. J. Comp. Neurol. 187:1979;117-143.
428. Pickel V.M., Segal M., Bloom F.E. A radioautographic study of the efferent pathways of the nucleus locus coeruleus. J. Comp. Neurol. 155:1974;15-42.
429. Pifl C., Schingnitz G., Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience. 44:1991;591-605.
430. Pineda J., Ugedo L., Garcia-Sevilla J.A. Stimulatory effects of clonidine, cirazoline and rilmenidine on locus coeruleus noradrenergic neurones: possible involvement of imidazoline-preferring receptors. Naunyn- Schmiedeberg's Arch. Pharmacol. 348:1993;134-140.
431. Plewnia C., Bartels M., Cohen L., Gerloff C. Noradrenergic modulation of human cortex excitability by the presynaptic alpha(2)-antagonist yohimbine. Neurosci. Lett. 307:2001;41-44.
432. Poewe W.H., Wenning G.K. The natural history of Parkinson's disease. Ann. Neurol. 44:1998;S1-S9.
433. Popovic M., Caballero-Bleda M., Puelles L., Popovic N. Importance of immunological and inflammatory processes in the pathogenesis and therapy of Alzheimer's disease. Int. J. Neurosci. 95:1998;203-236.
434. Popovik E., Haynes L.W. Survival and mitogenesis of neuroepithelial cells are influenced by noradrenergic but not cholinergic innervation in cultured embryonic rat neopallium. Brain Res. 853:2000;227-235.
435. Prado de Carvalho L., Zornetzer S.F. The involvement of the locus coeruleus in memory. Behav. Neural Biol. 31:1981;173-186.
436. Pycock C.J. Turning behaviour in animals. Neuroscience. 5:1980;461-514.
437. Rabins P.V. Noncognitive symptoms in Alzheimer's disease: definitions, treatments, and possible etiologies. Terry R., Katzman R., Bick K. Alzheimer Disease. 1994;419-444 Raven Press, New York.
438. Rajkowski J., Kubiak P., Aston-Jones G. Locus coeruleus activity in monkey: phasic and tonic changes are associated with altered vigilance. Brain Res. Bull. 35:1994;607-616.
439. Rammsayer T.H., Hennig J., Haag A., Lange N. Effects of noradrenergic activity on temporal information processing in humans. Q. J. Exp. Psychol., B. 54:2001;247-258.
440. Rascol O., Sieradzan K., Peyro-Saint-Paul H., Thalamas C., Brefel-Courbon C., Senard J.M., Ladure P., Montastruc J.L., Lees A. Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy. Mov. Disord. 13:1998;673-676.
441. Rascol O., Arnulf I., Peyro-Saint Paul H., Brefel-Courbon C., Vidailhet M., Thalamas C., Bonnet A.M., Descombes S., Bejjani B., Fabre N., Montastruc J.L., Agid Y. Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov. Disord. 16:2001;708-713.
442. Raskind M.A., Peskind E.R. Neurobiologic bases of noncognitive behavioral problems in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 8(Suppl. 3):1994;54-60.
443. Redfern W.S., MacKinnon A.C., Brown C.M., Martin A.B., Kilpatrick A.T., Clague R.U., Spedding M. Modulation of central noradrenergic function by RS-15385-197. Br. J. Pharmacol. 108:1993;526-533.
444. Reding M.J., Solomon B., Borucki S.J. Effect of dextroamphetamine on motor recovery after stroke. Neurology. 45:1995;A222.
445. Reisine T.D., Nagy J.I., Beaumont K., Fibiger H.C., Yamamura H.I. The localization of receptor binding sites in the substantia nigra and striatum of the rat. Brain Res. 177:1979;241-252.
446. Ricaurte G.A., Langston J.W., Delanney L.E., Irwin I., Peroutka S.J., Forno L.S. Fate of nigrostriatal neurons in young mature mice given 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: a neurochemical and morphological reassessment. Brain Res. 376:1986;117-124.
447. Riekkinen M., Riekkinen P., Sirvio J., Riekkinen P. Jr. Effects of combined methysergide and mecamylamine/scopolamine treatment on spatial navigation. Brain Res. 585:1992;322-326.
448. Riekkinen P. Jr., Laakso M.P., Jakala P. Clonidine impairs sustained attention and memory in Alzheimer's disease. Neuroscience. 92:1999;975-982.
449. Roach A.G., Doxey J.C., Strachan D.A., Cavero I. Sleeping times evoked by alpha adrenoceptor agonists in two-day-old chicks: an experimental model to evaluate full and partial agonists at central alpha-2 adrenoceptors. J. Pharmacol. Exp. Ther. 227:1983;421-428.
450. Robbins T.W., Everett B., Fray P., Gaskin M., Carli M., De La Riva C. The roles of central catecholamines in attention and learning. Spiegelstein M., Levy A. Behavioural Models and the Analysis of Drug Action. 1982;109-134 Elsevier, Amsterdam.
451. Robinson S.R., Bishop G.M. Abeta as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. Neurobiol. Aging. 23:2002;1051-1072.
452. Robinson T.E., Whishaw I.Q. Normalization of extracellular dopamine in striatum following recovery from a partial unilateral 6-OHDA lesion of the substantia nigra: a microdialysis study in freely moving rats. Brain Res. 450:1988;209-224.
453. Robinson T.E., Castaneda E., Whishaw I.Q. Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or methamphetamine: a review of evidence from microdialysis studies. Can. J. Psychol. 44:1990;253-275.
454. Room P., Postema F., Korf J. Divergent axon collaterals of rat locus coeruleus neurons: demonstration by a fluorescent double labeling technique. Brain Res. 221:1981;219-230.
455. Roos B.E., Steg G. The effect of L-3,3-dihydroxyphenylalanine and DL-5-hydroxytryptophan on rigidity and tremor induce by reserpine, cholorpromazine and phenoxybenzamine. Life Sci. 3:1964;251-260.
456. Rossner S., Ueberham U., Schliebs R., Perez-Polo J.R., Bigl V. The regulation of amyloid precursor protein metabolism by cholinergic mechanisms and neurotrophin receptor signaling. Prog. Neurobiol. 56:1998;541-569.
457. Ruiz-Ortega J.A., Ugedo L., Pineda J., Garcia-Sevilla J.A. The stimulatory effect of clonidine through imidazoline receptors on locus coeruleus noradrenergic neurones is mediated by excitatory amino acids and modulated by serotonin. Naunyn-Schmiedeberg's Arch. Pharmacol. 352:1995;121-126.
458. Sahakian B.J., Coull J.J., Hodges J.R. Selective enhancement of executive function by idazoxan in a patient with dementia of the frontal lobe type. J. Neurol. Neurosurg. Psychiatry. 57:1994;120-121.
459. Salm A.K., McCarthy K.D. The evidence for astrocytes as a target for central noradrenergic activity: expression of adrenergic receptors. Brain Res. Bull. 29:1992;265-275.
460. Saper C.B., Sorrentino D.M., German D.C., de Lacalle S. Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease. Ann. Neurol. 29:1991;577-584.
461. Sara S.J. Noradrenergic modulation of selective attention: its role in memory retrieval. Ann. N.Y. Acad. Sci. 444:1985;178-193.
462. Sara S.J., Devauges V. Idazoxan, an alpha-2 antagonist, facilitates memory retrieval in the rat. Behav. Neural Biol. 51:1989;401-411.
463. Savola J.-M., Hill M.P., Merivuori H., McGuire S.G., Crossman A.R., Brotchie J.M. JP-1730, a novel alpha-2 adrenergic anatgonist, reduces L-Dopa-induced dyskinesia in animal models of Parkinson's disease. Abstr. - Soc. Neurosci. 27:2001;531.
464. Scali C., Prosperi C., Vannucchi M.G., Pepeu G., Casamenti F. Brain inflammatory reaction in an animal model of neuronal degeneration and its modulation by an anti-inflammatory drug: implication in Alzheimer's disease. Eur. J. Neurosci. 12:2000;1900-1912.
465. Scheibel M.E., Scheibel A.B. Structural changes in the aging brain. Harman D., Ordy J.M. Aging. vol. 1:1975;11-37 Raven Press, New York.
466. Scheibel A.B., Tomiyasu U. A dendritic-vascular relationship in the substantia nigra. Exp. Neurol. 70:1980;717-720.
467. Schinder A.F., Poo M. The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci. 23:2000;639-645.
468. Schlegel J., Mohr E., Williams J., Mann U., Gearing M., Chase T.N. Guanfacine treatment of Alzheimer's disease. Clin. Neuropharmacol. 12:1989;124-128.
469. Schwartz J.P. Stimulation of nerve growth factor mRNA content in C6 glioma cells by a beta-adrenergic receptor and by cyclic AMP. Glia. 1:1988;282-285.
470. Schwartz J.P., Costa E. Regulation of nerve growth factor content in C6 glioma cells by beta-adrenergic receptor stimulation. Naunyn-Schmiedeberg's Arch. Pharmacol. 300:1977;123-129.
471. Schwartz J.P., Mishler K. Beta-adrenergic receptor regulation, through cyclic AMP, of nerve growth factor expression in rat cortical and cerebellar astrocytes. Cell. Mol. Neurobiol. 10:1990;447-457.
472. Schwartz J.P., Nishiyama N. Neurotrophic factor gene expression in astrocytes during development and following injury. Brain Res. Bull. 35:1994;403-407.
473. Scott S.A., Mufson E.J., Weingartner J.A., Skau K.A., Crutcher K.A. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J. Neurosci. 15:1995;6213-6221.
474. Segal R.A., Takahashi H., McKay R.D. Changes in neurotrophin responsiveness during the development of cerebellar granule neurons. Neuron. 9:1992;1041-1052.
475. Selby G. Clinical features. Stern G.M. Parkinson's Disease. 1990;333-388 Chapman & Hall Medical, London.
476. Selden N.R., Robbins T.W., Everitt B.J. Enhanced behavioral conditioning to context and impaired behavioral and neuroendocrine responses to conditioned stimuli following ceruleocortical noradrenergic lesions: support for an attentional hypothesis of central noradrenergic function. J. Neurosci. 10:1990;531-539.
477. Selkoe D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:2001;741-766.
478. Semkova I., Krieglstein J. Neuroprotection mediated via neurotrophic factors and induction of neurotrophic factors. Brain Res. Brain Res. Rev. 30:1999;176-188.
479. Seniuk N.A., Tatton W.G., Greenwood C.E. Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP. Brain Res. 527:1990;7-20.
480. Servan-Schreiber D., Printz H., Cohen J.D. A network model of catecholamine effects: gain, signal-to-noise ratio, and behavior. Science. 249:1990;892-895.
481. Shen P.J., Burazin T.C., Gundlach A.L. Noradrenergic regulation of immediate early gene expression in rat forebrain: differential effects of alpha 1- and alpha 2-adrenoceptor drugs. Brain Res. Mol. Brain Res. 28:1995;222-230.
482. Shipley M.T., Halloran F.J., de la Torre J. Surprisingly rich projection from locus coeruleus to the olfactory bulb in the rat. Brain Res. 329:1985;294-299.
483. Shirokawa T., Kasamatsu T. Concentration-dependent suppression by beta-adrenergic antagonists of the shift in ocular dominance following monocular deprivation in kitten visual cortex. Neuroscience. 18:1986;1035-1046.
484. Shirokawa T., Kasamatsu T. Reemergence of ocular dominance plasticity during recovery from the effects of propranolol infused in kitten visual cortex. Exp. Brain Res. 68:1987;466-476.
485. Siciliano R., Fornai F., Bonaccorsi I., Domenici L., Bagnoli P. Cholinergic and noradrenergic afferents influence the functional properties of the postnatal visual cortex in rats. Vis. Neurosci. 16:1999;1015-1028.
486. Siegel G.J., Chauhan N.B. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res. Brain Res. Rev. 33:2000;199-227.
487. Silverman P.B. On-off effects of dopamine receptor agonists in the hemi-parkinsonian rat. Eur. J. Pharmacol. 242:1993;31-36.
488. Simon H., Le Moal M., Calas A. Efferents and afferents of the ventral tegmental-A10 region studied after local injection of [3H]leucine and horseradish peroxidase. Brain Res. 178:1979;17-40.
489. Singer W. The brain as a self-organizing system. Eur. Arch. Psychiatr. Neurol. Sci. 236:1986;4-9.
490. Siniscalchi A., Badini I., Bianchi C., Beani L. Monoamines modulate the electrically-evoked efflux of 3H-choline from slices of guinea pig nucleus basalis magnocellularis. Naunyn-Schmiedeberg's Arch. Pharmacol. 350:1994;10-14.
491. Sirvio J., Jakala P., Mazurkiewicz M., Haapalinna A., Riekkinen P. Jr., Riekkinen P.J. Dose- and parameter-dependent effects of atipamezole, an alpha 2-antagonist, on the performance of rats in a five-choice serial reaction time task. Pharmacol. Biochem. Behav. 45:1993;123-129.
492. Smiley J.F., Subramanian M., Mesulam M.M. Monoaminergic-cholinergic interactions in the primate basal forebrain. Neuroscience. 93:1999;817-829.
493. Smith A.P., Wilson S.J., Glue P., Nutt D.J. The effects and after effects of the alpha 2-adrenoceptor antagonist idazoxan on mood, memory, and attention in normal volunteers. J. Psychopharmacol. 6:1992;376-381.
494. Smith D.E., Roberts J., Gage F.H., Tuszynski M.H. Age-associated neuronal atrophy occurs in the primate brain and is reversible by growth factor gene therapy. Proc. Natl. Acad. Sci. U. S. A. 96:1999;10893-10898.
495. Smith M.A., Joseph J.A., Perry G. Arson: tracking the culprit in Alzheimer's disease. Ann. N.Y. Acad. Sci. 924:2000;35-38.
496. Sofroniew M.V., Pearson R.C., Eckenstein F., Cuello A.C., Powell T.P. Retrograde changes in cholinergic neurons in the basal forebrain of the rat following cortical damage. Brain Res. 289:1983;370-374.
497. Soldani P., Fornai F. The functional anatomy of noradrenergic neurons in Parkinson's disease. Funct. Neurology. 14:1999;97-109.
498. Speciale S.G., Crowley W.R., O'Donohue T.L., Jacobowitz D.M. Forebrain catecholamine projections of the A5 cell group. Brain Res. 154:1978;128-133.
499. Sperlagh B., Sershen H., Lajtha A., Vizi E.S. Co-release of endogenous ATP and [3H]noradrenaline from rat hypothalamic slices: origin and modulation by alpha2-adrenoceptors. Neuroscience. 82:1998;511-520.
500. Spina M.B., Hyman C., Squinto S., Lindsay R.M. Brain-derived neurotrophic factor protects dopaminergic cells from 6-hydroxydopamine toxicity. Ann. N.Y. Acad. Sci. 648:1992;348-350.
501. Spina M.B., Squinto S.P., Miller J., Lindsay R.M., Hyman C. Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J. Neurochem. 59:1992;99-106.
502. Stanton P.K., Sarvey J.M. Depletion of norepinephrine, but not serotonin, reduces long-term potentiation in the dentate gyrus of rat hippocampal slices. J. Neurosci. 5:1985;2169-2176.
503. Stanton P.K., Sarvey J.M. Norepinephrine regulates long-term potentiation of both the population spike and dendritic EPSP in hippocampal dentate gyrus. Brain Res. Bull. 18:1987;115-119.
504. Starke K. Presynaptic autoreceptors in the third decade: focus on alpha2-adrenoceptors. J. Neurochem. 78:2001;685-693.
505. Stone E.A. Glial cells as targets of the central noradrenergic system. An update. Briley M., Marien M. Noradrenergic Mechanisms in Parkinson's Disease. 1994;173-189 CRC Press, Boca Ratonr.
506. Stone E.A., Ariano M.A. Are glial cells targets of the central noradrenergic system? A review of the evidence. Brain Res. Brain Res. Rev. 14:1989;297-309.
507. Strohmeyer R., Rogers J. Molecular and cellular mediators of Alzheimer's disease inflammation. J. Alzheimer's Dis. 3:2001;131-157.
508. Sugiyama H., Hainfellner J.A., Schmid-Siegel B., Budka H. Neuroaxonal dystrophy combined with diffuse Lewy body disease in a young adult. Clin. Neuropathol. 12:1993;147-152.
509. Sutherland R.J., Kolb B., Whishaw I.Q., Becker J.B. Cortical noradrenaline depletion eliminates sparing of spatial learning after neonatal frontal cortex damage in the rat. Neurosci. Lett. 32:1982;125-130.
510. Sutin E.L., Jacobowitz D.M. Neurochemicals in the dorsal pontine tegmentum. Prog. Brain Res. 88:1991;3-14.
511. Sutton R.L., Feeney D.M. Alpha-adrenergic agonists and antagonists affect recovery and maintenance of beam-walking ability after sensorimotor cortex ablation in the rat. Restor. Neurol. Neurosci. 4:1992;1-11.
512. Svensson T.H., Engberg G. Effect of nicotine on single cell activity in the noradrenergic nucleus locus coeruleus. Acta Physiol. Scand. (Suppl. 479):1980;31-34.
513. Swaab D.F., Lucassen P.J., Salehi A., Scherder E.J., van Someren E.J., Verwer R.W. Reduced neuronal activity and reactivation in Alzheimer's disease. Prog. Brain Res. 117:1998;343-377.
514. Swanson L.W., Hartman B.K. The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine-beta-hydroxylase as a marker. J. Comp. Neurol. 163:1975;467-505.
515. Sweet R.D., McDowell F.H., Feigenson J.S., Loranger A.W., Goodell H. Mental symptoms in Parkinson's disease during chronic treatment with levodopa. Neurology. 26:1976;305-310.
516. Szelenyi J. Cytokines and the central nervous system. Brain Res. Bull. 54:2001;329-338.
517. Tajrine D., Garofalo L., Cuello A.C., Ribeiro-da-Silva A. Responses of cortical noradrenergic and somatostinergic fibres and terminals to adjacent strokes and subsequent treatment with NGF and/or the ganglioside GM1. J. Neurosci. Res. 50:1997;627-642.
518. Takeuchi M., Sasaki S., Ito A., Osawa M., Kobayashi I., Maruyama S. An
519. Taquet H., Javoy-Agid F., Cesselin F., Hamon M., Legrand J.C., Agid Y. Microtopography of methionine-enkephalin, dopamine and noradrenaline in the ventral mesencephalon of human control and Parkinsonian brains. Brain Res. 235:1982;303-314.
520. Tassin J.P. Norepinephrine-dopamine interactions in the prefrontal cortex and the ventral tegmental area: relevance to mental diseases. Adv. Pharmacol. 42:1998;712-716.
521. Tassin J.P., Lavielle S., Herve D., Blanc G., Thierry A.M., Alvarez C., Berger B., Glowinski J. Collateral sprouting and reduced activity of the rat mesocortical dopaminergic neurons after selective destruction of the ascending noradrenergic bundles. Neuroscience. 4:1979;1569-1582.
522. Tellez S., Colpaert F., Marien M. The alpha 2-adrenoceptor antagonist, (+)-efaroxan, enhances acetylcholine release in the rat cortex in vivo. Eur. J. Pharmacol. 277:1995;113-116.
523. Tellez S., Colpaert F., Marien M. Acetylcholine release in the rat prefrontal cortex in vivo: modulation by alpha 2-adrenoceptor agonists and antagonists. J. Neurochem. 68:1997;778-785.
524. Tellez S., Colpaert F., Marien M. Alpha2-adrenoceptor modulation of cortical acetylcholine release in vivo. Neuroscience. 89:1999;1041-1050.
525. Temple S., Alvarez-Buylla A. Stem cells in the adult mammalian central nervous system. Curr. Opin. Neurobiol. 9:1999;135-141.
526. Thiffault C., Lamarre-Theroux L., Quirion R., Poirier J. L-Deprenyl and MDL72974 do not improve the recovery of dopaminergic cells following systemic administration of MPTP in mouse. Brain Res. Mol. Brain Res. 44:1997;238-244.
527. Thomas M.J., Moody T.D., Makhinson M., O'Dell T.J. Activity-dependent beta-adrenergic modulation of low frequency stimulation induced LTP in the hippocampal CA1 region. Neuron. 17:1996;475-482.
528. Thomas S.A., Palmiter R.D. Disruption of the dopamine beta-hydroxylase gene in mice suggests roles for norepinephrine in motor function, learning, and memory. Behav. Neurosci. 111:1997;579-589.
529. Thome J., Sakai N., Shin K., Steffen C., Zhang Y.J., Impey S., Storm D., Duman R.S. cAMP response element-mediated gene transcription is upregulated by chronic antidepressant treatment. J. Neurosci. 20:2000;4030-4036.
530. Tomonaga M. Neuropathology of the locus ceruleus: a semi-quantitative study. J. Neurol. 230:1983;231-240.
531. Torres E.M., Perry T.A., Blockland A., Wilkinson L.S., Wiley R.G., Lappi D.A., Dunnet S.B. Behavioural, histochemical and biochemical consequences of selective immunolesions in discrete regions of the basal forebrain cholinergic system. Neuroscience. 63:1994;95-122.
532. Troadec J.D., Marien M., Darios F., Hartmann A., Ruberg M., Colpaert F., Michel P.P. Noradrenaline provides long-term protection to dopaminergic neurons by reducing oxidative stress. J. Neurochem. 79:2001;200-210.
533. Troadec J.D., Marien M., Mourlevat S., Debeir T., Ruberg M., Colpaert F., Michel P.P. Activation of the mitogen-activated protein kinase (ERK(1/2)) signaling pathway by cyclic AMP potentiates the neuroprotective effect of the neurotransmitter noradrenaline on dopaminergic neurons. Mol. Pharmacol. 62:2002;1043-1052.
534. Tsacopoulos M., Magistretti P.J. Metabolic coupling between glia and neurons. J. Neurosci. 16:1996;877-885.
535. Turski L., Turski W.A. Towards an understanding of the role of glutamate in neurodegenerative disorders: energy metabolism and neuropathology. Experientia. 49:1993;1064-1072.
536. Tuszynski M.H., Gage F.H. Neurotrophic factors and neuronal loss: potential relevance to Alzheimer's disease. Terry R., Katzman R., Bick K. Alzheimer Disease. 1994;405-417 Raven Press, New York.
537. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol. Scand. (Suppl. 367):1971;69-93.
538. Unnerstall J.R., Kopajtic T.A., Kuhar M.J. Distribution of alpha 2 agonist binding sites in the rat and human central nervous system: analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. Brain Res. 319:1984;69-101.
539. van Praag H., Schinder A.F., Christie B.R., Toni N., Palmer T.D., Gage F.H. Functional neurogenesis in the adult hippocampus. Nature. 415:2002;1030-1034.
540. van Veldhuizen M.J., Feenstra M.G., Heinsbroek R.P., Boer G.J. In vivo microdialysis of noradrenaline overflow: effects of alpha-adrenoceptor agonists and antagonists measured by cumulative concentration-response curves. Br. J. Pharmacol. 109:1993;655-660.
541. Velley L., Cardo B. Improvement of learning 4 weeks after electrical stimulation of catecholaminergic structures: is the locus coeruleus implicated? Behav. Neural Biol. 27:1979;540-545.
542. Velley L., Cardo B. Long-term improvement of learning after early electrical stimulation of some central nervous structures: is the effect structure and age-dependent? Brain Res. Bull. 4:1979;459-466.
543. Verhagen-Kamerbeek W.D.J., de Haas J.R.A., Teelken A.W., Lakke J.P.W.F. The effects of the selective noradrenergic neurotoxin DSP-4 on the central noradrenergic and dopaminergic system of the rat: a microdialysis study. Rollema H., Westerink B.H.C. Monitoring Molecules in Neuroscience: Proceedings of the 5th International Conference on In Vivo Methods, The Netherlands. 1991;409-412.
544. Walker-Batson D., Smith P., Curtis S., Unwin H., Greenlee R. Amphetamine paired with physical therapy accelerates motor recovery after stroke. Further evidence. Stroke. 26:1995;2254-2259.
545. Wallace W., Haroutunian V. Using the subcortically lesioned rat cortex to understand the physiological role of amyloid precursor protein. Behav. Brain Res. 57:1993;199-206.
546. Wallace W., Ahlers S.T., Gotlib J., Bragin V., Sugar J., Gluck R., Shea P.A., Davis K.L., Haroutunian V. Amyloid precursor protein in the cerebral cortex is rapidly and persistently induced by loss of subcortical innervation. Proc. Natl. Acad. Sci. U. S. A. 90:1993;8712-8716.
547. Waterhouse B.D., Moises H.C., Woodward D.J. Alpha-receptor-mediated facilitation of somatosensory cortical neuronal responses to excitatory synaptic inputs and iontophoretically applied acetylcholine. Neuropharmacology. 20:1981;907-920.
548. Waterhouse B.D., Moises H.C., Woodward D.J. Interaction of serotonin with somatosensory cortical neuronal responses to afferent synaptic inputs and putative neurotransmitters. Brain Res. Bull. 17:1986;507-518.
549. Waterhouse B.D., Sessler F.M., Cheng J.T., Woodward D.J., Azizi S.A., Moises H.C. New evidence for a gating action of norepinephrine in central neuronal circuits of mammalian brain. Brain Res. Bull. 21:1988;425-432.
550. Waterhouse B.D., Mouradian R., Sessler F.M., Lin R.C. Differential modulatory effects of norepinephrine on synaptically driven responses of layer V barrel field cortical neurons. Brain Res. 868:2000;39-47.
551. Weisskopf M.G., Castillo P.E., Zalutsky R.A., Nicoll R.A. Mediation of hippocampal mossy fiber long-term potentiation by cyclic AMP. Science. 265:1994;1878-1882.
552. Wenk G.L., Stoehr J.D., Quintana G., Mobley S., Wiley R.G. Behavioral, biochemical, histological, and electrophysiological effects of 192 IgG-saporin injections into the basal forebrain of rats. J. Neurosci. 14:1994;5986-5995.
553. Wenning G.K., Quinn N., Magalhaes M., Mathias C., Daniel S.E. Minimal change multiple system atrophy. Mov. Disord. 9:1994;161-166.
554. Whishaw I.Q., O'Connor W.T., Dunnett S.B. Disruption of central cholinergic systems in the rat by basal forebrain lesions or atropine: effects on feeding, sensorimotor behaviour, locomotor activity and spatial navigation. Behav. Brain Res. 17:1985;103-115.
555. Whitehouse P.J., Price D.L., Struble R.G., Clark A.W., Coyle J.T., Delon M.R. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science. 215:1982;1237-1239.
556. Wilcock G.K., Esiri M.M., Bowen D.M., Smith C.C. Alzheimer's disease. Correlation of cortical choline acetyltransferase activity with the severity of dementia and histological abnormalities. J. Neurol. Sci. 57:1982;407-417.
557. Williams L.R., Varon S., Peterson G.M., Wictorin K., Fischer W., Bjorklund A., Gage F.H. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc. Natl. Acad. Sci. U. S. A. 83:1986;9231-9235.
558. Winkler J., Suhr S.T., Gage F.H., Thal L.J., Fisher L.J. Essential role of neocortical acetylcholine in spatial memory. Nature. 375:1995;484-487.
559. Wood P.L., Kim H.S., Altar C.A. In vivo assessment of dopamine and norepinephrine release in rat neocortex: gas chromatography-mass spectrometry measurement of 3-methoxytyramine and normetanephrine. J. Neurochem. 48:1987;574-579.
560. Wu Z.L., Thomas S.A., Villacres E.C., Xia Z., Simmons M.L., Chavkin C., Palmiter R.D., Storm D.R. Altered behavior and long-term potentiation in type I adenylyl cyclase mutant mice. Proc. Natl. Acad. Sci. U. S. A. 92:1995;220-224.
561. Yavich L., Sirvio J., Haapalinna A., Riekkinen P. Sr. Some unusual effects of alpha 2-adrenergic drugs on cortical high voltage spindles in rats. Eur. Neuropsychopharmacol. 4:1994;535-538.
562. Yavich L., Lappalainen R., Sirvio J., Haapalinna A., MacDonald E. Alpha2-adrenergic control of dopamine overflow and metabolism in mouse striatum. Eur. J. Pharmacol. 339:1997;113-119.
563. Yavich L., Sirvio J., Haapalinna A., Ylinen A., Mannisto P.T. Atipamezole, an alpha2-adrenoceptor antagonist, augments the effects of L-DOPA on evoked dopamine release in rat striatum. Eur. J. Pharmacol. 462:2003;83-89.
564. Zaborszky L., Cullinan W.E., Luine V.N. Catecholaminergic-cholinergic interaction in the basal forebrain. Prog. Brain Res. 98:1993;31-49.
565. Zaborszky L., Kiss J., Rosin D.L. Alpha2A adrenergic receptors are present in the basal forebrain cholinergic projection neurons. Abstr. - Soc. Neurosci. 21:1995;69.
566. Zaborszky L., Pang K., Somogyi J., Nadasdy Z., Kallo I. The basal forebrain corticopetal system revisited. Ann. N.Y. Acad. Sci. 877:1999;339-367.
567. Zarow C., Lyness S.A., Mortimer J.A., Chui H.C. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60:2003;337-341.
568. Zhang X., Yu P.H. Depletion of NOS activity in the rat dentate gyrus neurons by DSP-4 and protection by deprenyl. Brain Res. Bull. 38:1995;307-311.
569. Zhu X.O., Waite P.M. Cholinergic depletion reduces plasticity of barrel field cortex. Cereb. Cortex. 8:1998;63-72.
570. Zigmond M.J., Abercrombie E.D., Berger T.W., Grace A.A., Stricker E.M. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci. 13:1990;290-296.
571. Zigova T., Pencea V., Wiegand S.J., Luskin M.B. Intraventricular administration of BDNF increases the number of newly generated neurons in the adult olfactory bulb. Mol. Cell. Neurosci. 11:1998;234-245.
572. Zornetzer S.F. Catecholamine system involvement in age-related memory dysfunction. Ann. N.Y. Acad. Sci. 444:1985;242-254.
573. Zweig R.M., Ross C.A., Hedreen J.C., Steele C., Cardillo J.E., Whitehouse P.J., Folstein M.F., Price D.L. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann. Neurol. 24:1998;233-242.
574. Zweig R.M., Ross C.A., Hedreen J.C., Peyser C., Cardillo J.E., Folstein S.E., Price D.L. Locus coeruleus involvement in Huntington's disease. Arch. Neurol. 49:1992;152-156.